UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2019~~2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 000-09908

TOMI ENVIRONMENTAL SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Florida	59-1947988
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

9454 Wilshire Blvd., Penthouse, Beverly Hills, CA 90212
(Address of principal executive offices) (Zip Code)

(800) 525-1698
(Registrant’s telephone number, including area code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		TOMZ		OTC Markets Group Inc.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May ~~9, 2019,~~6, 2020, the registrant had ~~124,700,418~~133,517,083 shares of common stock outstanding.

QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, ~~2019~~2020

TABLE OF CONTENTS


		Page


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS		2

PART I	FINANCIAL INFORMATION

Item 1	Financial Statements.	3

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2524

Item 3	Quantitative and Qualitative Disclosures About Market Risk.	38 37

Item 4	Controls and Procedures.	38 37

PART II	OTHER INFORMATION

Item 1	Legal Proceedings.	3938

Item 1A	Risk Factors.	3938

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds.	3938

Item 3	Defaults Upon Senior Securities.	3938

Item 4	Mine Safety Disclosures.	3938

Item 5	Other Information.	39

~~Item 6~~	~~Exhibits.~~	3938

~~SIGNATURES~~ Item 6	40Exhibits.	38

SIGNATURES		39

EXHIBIT INDEX		4140

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and we intend that such forward looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Form 10-Q, except for historical information, may be deemed forward-looking statements. You can generally identify forward-looking statements as statements containing the words “will,” “would,” “believe,” “expect,” “estimate,” “anticipate,” “intend,” “estimate,” “assume,” “can,” “could,” “plan,” “predict,” “should” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements.

The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” in our most recent Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

PART I: FINANCIAL INFORMATION

Item 1. Financial Statements.

~~PART I: FINANCIAL INFORMATION~~

~~Item 1. Financial Statements.~~

TOMI ENVIRONMENTAL SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET

ASSETS

Current Assets:

March 31,
2019
(Unaudited)

December 31,
2018

Cash and Cash Equivalents
$1,195,938
$2,004,938
Accounts Receivable - net
  2,027,700
  2,145,622
Inventories (Note 3)
  2,393,188
  2,682,014
Deposits
  188,716
  109,441
Prepaid Expenses
  259,140
  301,797
       Total Current Assets
  6,064,682
  7,243,812



Property and Equipment – net (Note 4)
  1,528,907
  1,588,591



Other Assets:


Intangible Assets – net (Note 5)
  1,143,439
  1,235,816
Operating Lease - Right of Use Asset (Note 6)
  703,823
  -
Capitalized Software Development Costs (Note 7)
  125,704
  -
Other Assets
  76,309
  11,395
     Total Other Assets
  2,049,275
  1,247,211
Total Assets
$9,642,863
$10,079,614



LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:


  Accounts Payable
$657,798
$1,133,649
  Accrued Expenses and Other Current Liabilities (Note 12)
  580,426
  415,199
  Accrued Officers Compensation
  29,792
  70,000
  Accrued Interest (Note 8)
  16,667
  66,667
  Customer Deposits
  -
  1,486
  Current Portion of Long-Term Operating Lease
  23,436
  -
   Deferred Rent
  -
  13,215
     Total Current Liabilities
  1,308,119
  1,700,216



Long-Term Liabilities:


  Long-Term Operating Lease, Net of Current Portion (Note 6)
  1,089,316
  -
  Deferred Rent and Tenant Improvement Allowances
  -
  401,734

Convertible Notes Payable, net of discount of $0 and $17,534


     at March 31, 2019 and December 31, 2018, respectively (Note 8)
  5,000,000
  4,982,466
     Total Long-Term Liabilities
  6,089,316
  5,384,200
     Total Liabilities
  7,397,435
  7,084,416



Commitments and Contingencies
  -
  -



Shareholders’ Equity:


      Cumulative Convertible Series A Preferred Stock;


par value $0.01 per share share, 1,000,000 shares authorized; 510,000 shares issued
       and outstanding at March 31, 2019 and December 31, 2018
  5,100
  5,100

Cumulative Convertible Series B Preferred Stock; $1,000 stated value;



      7.5% Cumulative dividend; 4,000 shares authorized; none issued


       and outstanding at March 31, 2019 and December 31, 2018
  -
  -

Common stock; par value $0.01 per share, 200,000,000 shares authorized;



      124,690,418 and 124,290,418 shares issued and outstanding


       at March 31, 2019 and December 31, 2018, respectively.
  1,246,904
  1,242,904
     Additional Paid-In Capital
  43,129,467
  42,948,705
     Accumulated Deficit
  (42,136,043)
  (41,201,511)
     Total Shareholders’ Equity
  2,245,428
  2,995,198
Total Liabilities and Shareholders’ Equity
$9,642,863
$10,079,614

ASSETS
Current Assets:	March 31, 2020 (Unaudited)	December 31, 2019
Cash and Cash Equivalents	$3,755,816	$897,223
Accounts Receivable - net	3,146,197	1,494,658
Inventories (Note 3)	635,529	2,315,214
Vendor Deposits (Note 4)	1,266,560	141,052
Prepaid Expenses	170,856	187,664
Total Current Assets	8,974,958	5,035,811

Property and Equipment – net (Note 5))	1,257,831	1,367,864

Other Assets:
Intangible Assets – net (Note 6)	845,663	939,010
Operating Lease - Right of Use Asset (Note - 7)	664,198	674,471
Capitalized Software Development Costs - net (Note 8)	83,803	94,278
Other Assets	122,957	114,033
Total Other Assets	1,716,621	1,821,792
Total Assets	$11,949,410	$8,225,467

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts Payable	$832,177	$713,222
Accrued Expenses and Other Current Liabilities (Note 13)	655,736	450,112
Accrued Officers Compensation	30,383	-
Accrued Interest (Note 9)	-	66,667
Customer Deposits (Note 15)	1,017,533	-
Current Portion of Long-Term Operating Lease	73,851	71,510
Convertible Notes Payable, net of discount of $0
at December 31, 2019 (Note 9)	-	5,000,000
Total Current Liabilities	2,609,680	6,301,511

Long-Term Liabilities:
Long-Term Operating Lease, Net of Current Portion (Note 7)	1,015,465	1,034,413
Total Long-Term Liabilities	1,015,465	1,034,413
Total Liabilities	3,625,145	7,335,924

Commitments and Contingencies	-	-

Shareholders’ Equity:
Cumulative Convertible Series A Preferred Stock;
par value $0.01 per share, 1,000,000 shares authorized; 510,000 shares issued
and outstanding at March 31, 2020 and December 31, 2019	5,100	5,100
Cumulative Convertible Series B Preferred Stock; $1,000 stated value;
7.5% Cumulative dividend; 4,000 shares authorized; none issued
and outstanding at March 31, 2020 and December 31, 2019	-	-
Common stock; par value $0.01 per share, 250,000,000 shares authorized;
133,517,083 and 124,700,418 shares issued and outstanding
at March 31, 2020 and December 31, 2019, respectively.	1,335,170	1,247,004
Additional Paid-In Capital	47,863,977	43,136,683
Accumulated Deficit	(40,879,982)	(43,499,244)
Total Shareholders’ Equity	8,324,265	889,543
Total Liabilities and Shareholders’ Equity	$11,949,410	$8,225,467

The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

	For The Three Months Ended
	March 31,
	2020	2019

Sales, net	$7,053,418	$1,252,658
Cost of Sales	2,565,410	493,310
Gross Profit	4,488,008	759,348

Operating Expenses:
Professional Fees	136,125	105,481
Depreciation and Amortization	171,909	176,845
Selling Expenses	378,645	441,671
Research and Development	59,458	92,577
Equity Compensation Expense (Note 10)	182,772	80,917
Consulting Fees	81,545	35,006
General and Administrative	818,145	694,880
Total Operating Expenses	1,828,599	1,627,377
Income (loss) from Operations	2,659,409	(868,030)

Other Income (Expense):
Amortization of Debt Discounts	-	(17,534)
Interest Income	542	1,030
Interest Expense	(40,689)	(50,000)
Total Other Income (Expense)	(40,147)	(66,504)

Income (loss) before income taxes	2,619,261	(934,532)
Provision for Income Taxes (Note 16)	-	-
Net income (loss)	$2,619,261	$(934,532)

Net income (loss) Per Common Share
Basic	$0.02��	$(0.01)
Diluted	$0.02	$(0.01)

Basic Weighted Average Common Shares Outstanding	126,802,819	124,659,307
Diluted Weighted Average Common Shares Outstanding	144,941,677	124,659,307

The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED MARCH 31, 2020

(UNAUDITED)

~~CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS~~

~~(UNAUDITED)~~

	Series A Preferred		Common Stock		Additional Paid in	Accumulated	Total Shareholders'
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2019	510,000	$5,100	124,700,418	$1,247,004	$43,136,683	$(43,499,243)	$889,543

Equity Compensation					209,961		209,961
Common Stock Issued for Services Provided			400,000	4,000	44,000		48,000
Conversion of Notes Payable into Common Stock			8,333,332	83,333	4,416,667		4,500,000
Warrants exercised			83,333	833	56,667		57,500
Net Income for the three months ended March 31, 2020						2,619,261	2,619,261
Balance at March 31, 2020	510,000	$5,100	133,517,083	$1,335,170	$47,863,978	$(40,879,982)	$8,324,265

For The Three Months Ended

March 31,

2019

2018

   Sales, net
$1,252,658
$1,312,466
   Cost of Sales
  493,310
  491,659
   Gross Profit
  759,348
  820,807



Operating Expenses:


   Professional Fees
  105,481
  106,458
   Depreciation and Amortization
  176,845
  162,738
   Selling Expenses
  441,670
  204,005
   Research and Development
  92,577
  132,487
   Equity Compensation Expense (Note 9)
  80,917
  12,685
   Consulting Fees
  35,006
  35,026
   General and Administrative
  694,880
  663,887
Total Operating Expenses
  1,627,376
  1,317,287
Loss from Operations
  (868,028)
  (496,480)



Other Income (Expense):


   Amortization of Debt Discounts
  (17,534)
  (8,037)
   Interest Income
  1,030
  1,198
   Interest Expense
  (50,000)
  (60,000)
Total Other Income (Expense)
  (66,504)
  (66,839)



Net Loss
$(934,532)
$(563,319)



Loss Per Common Share


   Basic and Diluted
$(0.01)
$(0.00)






Basic and Diluted Weighted Average Common Shares Outstanding
  124,659,307
  122,229,959

The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF ~~SHAREHOLDERS’ EQUITY~~CASH FLOWS

~~FOR THE THREE MONTHS ENDED MARCH 31, 2019~~(UNAUDITED )

~~(UNAUDITED)~~

	For the Three Months Ended March 31,
	2020	2019
Cash Flow From Operating Activities:
Net Income (Loss)	$2,619,261	$(934,532)
Adjustments to Reconcile Net Income (Loss) to		.
Net Cash Provided by (Used in) Operating Activities:
Depreciation and Amortization	171,909	176,845
Amortization of Lease Liability	39,329	39,644
Amortization of Debt Discount	-	17,534
Amortization of Software Costs	10,475	-
Equity Compensation Expense	182,772	80,917
Value of Equity Issued for Services	48,000	44,000
Reserve for Bad Debt	25,000	(105,000)
Inventory Reserve	(100,000)	-
Changes in Operating Assets and Liabilities:
Decrease (Increase) in:
Accounts Receivable	(1,676,539)	222,922
Inventory	1,815,942	288,827
Prepaid Expenses	16,807	6,792
Vendor Deposits	(1,125,508)	(79,275)
Other Assets	(8,924)	(64,914)
Increase (Decrease) in:
Accounts Payable	118,955	(475,851)
Accrued Expenses	232,813	225,072
Accrued Interest	(66,667)	(50,000)
Accrued Officer Compensation	30,383	(40,208)
Customer Deposits	1,017,533	(1,486)
Lease Liability	(35,865)	-

Net Cash Provided By (Used in) Operating Activities	3,315,678	(648,714)

Cash Flow From Investing Activities:
Capitalized Software Costs	-	(125,704)
Purchase of Property and Equipment	(14,585)	(34,582)
Net Cash (Used in) Investing Activities	(14,585)	(160,286)

The accompanying notes are an integral part of the condensed consolidated financial statements.

Series A Preferred

Common Stock

Shares

Amount

Shares

Amount

Additional Paid
in Capital

Accumulated
Deficit

Total Shareholders’
Equity

Balance at December 31, 2018
  510,000
$5,100
  124,290,418
$1,242,904
$42,948,705
$(41,201,511)
$2,995,198








Equity Compensation




  140,762

  140,762
Common Stock Issued for Services Provided


  400,000
  4,000
  40,000

  44,000
Net Loss for the three months ended March 31, 2019





  (934,532)
  (934,532)
Balance at March 31, 2019
  510,000
$5,100
  124,690,418
$1,246,904
$43,129,467
$(42,136,043)
$2,245,428

TOMI ENVIRONMENTAL SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS – CONTINUED

(UNAUDITED)

	For the Three Months Ended March 31,
Cash Flow From Financing Activities:	2020	2019
Proceeds from Exercise of Warrants	57,500	-
Repayment of Principal Balance on Convertible Note	(500,000)	-
Net Cash Used in Financing Activities	(442,500)	-
Increase (Decrease) In Cash and Cash Equivalents	2,858,594	(809,000)
Cash and Cash Equivalents - Beginning	897,223	2,004,938
Cash and Cash Equivalents – Ending	$3,755,816	$1,195,938

Supplemental Cash Flow Information:
Cash Paid for Interest	$107,356	$100,000
Cash Paid for Income Taxes	$-	$800
Non-Cash Investing and Financing Activities:
Accrued Equity Compensation	$27,189	$59,845
Conversion of Note Payable into Common Stock	$4,500,000	$-
Equipment, net Transferred to Inventory	$36,256	$-

The accompanying notes are an integral part of the condensed consolidated financial statements.

~~TOMI ENVIRONMENTAL SOLUTIONS, INC.~~

~~CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS~~

~~(UNAUDITED)~~

For the Three Months Ended

March 31,

2019

2018

Cash Flow from Operating Activities:

  Net Loss
$(934,532)
$(563,319)
  Adjustments to Reconcile Net Loss to


     Net Cash Used In Operating Activities:


      Depreciation and Amortization
  176,845
  162,738
      Lease Expense
  39,644
  -
      Amortization of Debt Discount
  17,534
  8,037
      Equity Compensation Expense
  80,917
  13,590
      Value of Equity Issued for Services
  44,000
  30,000
       Reserve for Bad Debt
  (105,000)
  -
Changes in Operating Assets and Liabilities:


      Decrease (Increase) in:


         Accounts Receivable
  222,922
  (394,453)
         Inventory
  288,827
  245,271
         Prepaid Expenses
  6,792
  (6,266)
         Deposits
  (79,275)
  (15,714)
         Other Assets
  (64,914)
  -
      Increase (Decrease) in:


         Accounts Payable
  (475,851)
  (116,927)
         Accrued Expenses
  225,072
  20,725
         Accrued Interest
  (50,000)
  (64,000)
         Accrued Officer Compensation
  (40,208)
  -
         Deferred Rent
  -
  (781)
         Customer Deposits
  (1,486)
  (1,484)
Net Cash Used in Operating Activities
  (648,714)
  (682,583)



Cash Flow From Investing Activities:


   Capitalized Software Costs
  (125,704)
  -
   Purchase of Property and Equipment
  (34,582)
  -
Net Cash Used in Investing Activities
  (160,286)
  -

~~The accompanying notes are an integral part of the condensed consolidated financial statements.~~

~~TOMI ENVIRONMENTAL SOLUTIONS, INC.~~

~~CONDENDSED CONSOLIDATED STATEMENT OF CASH FLOWS – CONTINUED~~

~~(UNAUDITED)~~

For the Three Months
Ended March 31,

2019

2018

Cash Flow From Financing Activities:
  -
  -
(Decrease) In Cash and Cash Equivalents
  (809,000)
  (682,583)
Cash and Cash Equivalents - Beginning
  2,004,938
  4,550,003
Cash and Cash Equivalents – Ending
$1,195,938
$3,867,420



Supplemental Cash Flow Information:


   Cash Paid For Interest
$100,000
$124,000
   Cash Paid for Income Taxes
$800
$800
Non-Cash Investing and Financing Activities:


     Right of Use Asset Arising from Adoption of ASC 842
$714,421
$-
Warrants and Options as Consideration for Accrued Expenses
$59,845
$-

~~The accompanying notes are an integral part of the condensed consolidated financial statements.~~

TOMI ENVIRONMENTAL SOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. DESCRIPTION OF BUSINESS

TOMI Environmental Solutions, Inc., a Florida corporation (“TOMI”, the “Company”, “we”, “our” and “us”) is a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, under which it manufactures, licenses, services and sells its SteraMist™® brand of products, including ~~SteraMist™~~SteraMist® BIT™, a hydrogen peroxide-based mist and fog.

Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ is registered with the U.S. Environmental Protection Agency (“EPA”) and uses a low percentage hydrogen peroxide as its only active ingredient to produce a fog composed mostly of a hydroxyl radical (.OH ion), known as ionized Hydrogen Peroxide (“iHP™”). Represented by the SteraMist™® brand of products, ~~iHP™~~ iHP™produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI’s products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, bio-safety labs, pharmaceutical facilities, meat and produce processing facilities, universities and research facilities, vivarium labs, all service industries including cruise ships, office buildings, hotel and motel rooms, schools, restaurants, military barracks, police and fire departments, and athletic facilities. TOMI products are also used in single-family homes and multi-unit residences.

TOMI’s mission is to help its customers create a healthier world through its product line in its divisions (Healthcare, Life Sciences, TOMI Service Network and Food Safety).

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The interim unaudited condensed consolidated financial statements included herein, presented in accordance with generally accepted accounting principles utilized in the United States of America (“GAAP”), and stated in U.S. dollars, have been prepared by the Company, without an audit, pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, ~~2018~~2019 and notes thereto which are included in the Annual Report on Form 10-K previously filed with the SEC on ~~April 1, 2019.~~March 30, 2020. The Company follows the same accounting policies in the preparation of interim reports. The results of operations for the interim periods covered by this Form 10-Q may not necessarily be indicative of results of operations for the full fiscal year or any other interim period.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of TOMI and its wholly-owned subsidiary, TOMI Environmental Solutions, Inc., a Nevada corporation. All significant intercompany accounts and transactions have been eliminated in consolidation.

Reclassification of Accounts

Certain reclassifications have been made to prior-year comparative financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or financial position.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the accompanying condensed consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, inventory, fair values of financial instruments, intangible assets, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes, and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of our assets and liabilities.

Fair Value Measurements

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

Level 1:

Quoted prices in active markets for identical assets or liabilities.

~~Level 2:~~

Level2:

Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

Level 3:

Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued ~~expenses and convertible debt.~~expenses. All these items were determined to be Level 1 fair value measurements.

The carrying amounts of cash and cash equivalents, accounts receivable, ~~and~~ accounts payable and accrued expenses approximated fair value because of the short maturity of these instruments. ~~The recorded value of convertible debt approximates its fair value as the terms and rates approximate market rates (See Note 8).~~

Cash and Cash Equivalents

For purposes of the statement of cash flows, cash and cash equivalents includes cash on hand, held at financial institutions and other liquid investments with original maturities of three months or less. At times, these deposits may be in excess of insured limits.

Accounts Receivable

Our accounts receivable are typically from credit worthy customers or, for certain international customers, are supported by pre-payments. For those customers to whom we extend credit, we perform periodic evaluations of them and maintain allowances for potential credit losses as deemed necessary. We have a policy of reserving for doubtful accounts based on our best estimate of the amount of potential credit losses in existing accounts receivable. We periodically review our accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Bad debt expense for the three months ended March 31, 2020 and 2019 was $25,000 and ~~2018 was~~ $58,490, ~~and $0,~~ respectively.

At March 31, ~~2019~~2020 and December 31, ~~2018,~~2019, the allowance for doubtful accounts was ~~$195,000~~$135,000 and ~~$300,000,~~$110,000, respectively.

As of March 31, ~~2019 and~~2020, one customer accounted for 12% of accounts receivable. As of December 31, ~~2018, two~~2019, three customers accounted for ~~41% and~~ 37% of accounts ~~receivable, respectively.~~receivable.

~~Two~~One customer/distributor accounted for 31% of net revenue for the three months ended March 31, 2020 and two customers accounted for 45% of net revenue for the three months ended March 31, ~~2019 and three customers accounted for 33% of net revenue for the three months ended March 31, 2018.~~2019.

Inventories

Inventories are valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventories consist primarily of finished goods.

We expense costs to maintain certification to cost of goods sold as incurred.

We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories may not be usable. Our reserve for obsolete inventory was $0 and $100,000 as of March 31, ~~2019~~2020 and December 31, ~~2018.~~2019, respectively.

Property and Equipment

We account for property and equipment at cost less accumulated depreciation. We compute depreciation using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation for equipment, furniture and fixtures and vehicles commences once placed in service for its intended use. Leasehold improvements are amortized using the straight-line method over the lives of the respective leases or service lives of the improvements, whichever is shorter.

Leases

In February 2016, the FASB issued ASU No. 2016-02 (“ASC 842”), Leases, to require lessees to recognize all leases, with certain exceptions, on the balance sheet, while recognition on the statement of operations will remain similar to current lease accounting. Subsequently, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases, ASU No. 2018-11, Targeted Improvements, ASU No. 2018-20, Narrow-Scope Improvements for Lessors, and ASU 2019-01, Codification Improvements, to clarify and amend the guidance in ASU No. 2016-02. ASC 842 eliminates real estate-specific provisions and modifies certain aspects of lessor accounting. This standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We adopted ASC 842 as of January 1, 2019 using the modified retrospective basis with a cumulative effect adjustment as of that date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed us to carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements. Accordingly, previously reported financial statements, including footnote disclosures, have not been recast to reflect the application of the new standard to all comparative periods presented.

Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease liabilities are recorded as current portion of long-term operating lease, and within long-term liabilities as long-term operating lease, net of current portion on our condensed consolidated balance sheet as of March 31, 2020 and December 31, 2019.

We have elected not to present short-term leases on the condensed consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that we are reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of our leases do not provide an implicit rate of return, we used our incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments.

Adoption of the new lease standard on January 1, 2019 had a material impact on our interim unaudited condensed consolidated financial statements. The most significant impacts related to the recognition of right-of-use ("ROU") asset of $714,421 and lease liability of $678,556 for our operating lease on the consolidated balance sheet. We also reclassified prepaid expenses of $35,865 and deferred rent balance, including tenant improvement allowances, and other liability balances of $414,949 relating to our existing lease arrangements as of December 31, 2018, into the ROU asset balance as of January 1, 2019. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The standard did not materially impact our consolidated statement of operations and consolidated statement of cash flows.

~~The cumulative effect of the changes made to our consolidated balance sheet as of January 1, 2019 for the adoption of the new lease standard was as follows:~~

Balances at
December 31,
2018

Effect of Adoption of New Lease Standard

Balances at
January 1,
2019

Assets

  Prepaid Expenses
$301,797
$(35,865)
$265,932
  Operating Lease Right of Use Asset
$-
$714,421
$714,421
Liabilities



  Deferred Rent
$13,215
$(13,215)
$-
  Current Portion of Long-Term Operating Lease
  -
  -
  -
  Deferred Rent and Tenant Improvement Allowances
$401,734
$(401,734)
$-
Long-Term Operating Lease, Net of Current Portion
  -
$1,093,505
$1,093,505
Shareholders' Equity



  Accumulated Deficit
$(41,201,511)
$-
$(41,201,511)

Capitalized Software Development Costs

In accordance with ASC 985-20 regarding the development of software to be sold, leased, or marketed, the Company expenses such costs as they are incurred until technological feasibility has been established, at and after which time those costs are capitalized until the product is available for general release to customers. The periodic expense for the amortization of capitalized software development costs will be included in cost of sales.

~~Accounts Payable~~

~~As of March 31, 2019, two vendors accounted for approximately 40% of accounts payable. As of December 31, 2018, three vendors accounted for approximately 63% of accounts payable~~

~~One vendor accounted for approximately 67% and 70% of cost of sales~~ Amortization expense for the three months ended March 31, 2020 was $10,475.

Accounts Payable

As of March 31, 2020, and December 31, 2019, one vendor accounted for approximately 33% and ~~2018,~~40% of accounts payable, respectively.

For the three months ended March 31, 2020 and 2019, one vendor accounted for 89% and 67% of cost of sales, respectively.

Accrued Warranties

Accrued warranties represent the estimated costs, if any, that will be incurred during the warranty period of our products. We estimate the expected costs to be incurred during the warranty period and record the expense to the condensed consolidated statement of operations at the date of sale. Our manufacturer assumes the warranty against product defects for one year from date of sale, which we extend to our customers upon sale of the product. We assume responsibility for product reliability and results. As of March 31, ~~2019~~2020, and December 31, ~~2018,~~2019, our warranty reserve was $60,000 and $30,000, respectively (See Note ~~13)~~14).

Income Taxes

Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are, on a more likely than not basis, not expected to be realized in accordance with Accounting Standards Codification (“ASC”) guidance for income taxes. Net deferred tax benefits have been fully reserved at March 31, ~~2019~~2020 and December 31, ~~2018.~~2019. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

Net ~~Loss~~Income (Loss) Per Share

Basic net ~~loss~~income or (loss) per share is computed by dividing the Company’s net ~~loss~~income or (loss) by the weighted average number of shares of common stock outstanding during the period presented. Diluted ~~loss~~income or (loss) per share is based on the treasury stock method and includes the effect from potential issuance of shares of common stock, such as shares issuable pursuant to the exercise of options and warrants and conversions of preferred stock or debentures.

Potentially dilutive securities as of March 31, 2020 consisted of 16,798,858 shares of common stock issuable upon exercise of outstanding warrants, 830,000 shares of common stock issuable upon outstanding options and 510,000 shares of common stock issuable upon conversion of outstanding shares of Preferred A stock (“Convertible Series A Preferred Stock”).

Potentially dilutive securities as of March 31, 2019 consisted of 9,259,250 shares of common stock from convertible debentures, 26,800,611 shares of common stock issuable upon exercise of outstanding warrants, 620,000 shares of common stock issuable upon outstanding options and 510,000 shares of common stock issuable upon conversion of outstanding shares of Preferred A stock (“Convertible Series A Preferred Stock”). Diluted and basic weighted average shares are the same, as potentially dilutive shares are anti-dilutive.

Potentially dilutive securities as of March 31, 2018 consisted of 11,111,100 shares of common stock from convertible debentures, 35,251,411 shares of common stock issuable upon exercise of outstanding warrants, 320,000 shares of common stock issuable upon outstanding options and 510,000 shares of common stock issuable upon conversion of outstanding shares of Preferred A stock (“Convertible Series A Preferred Stock”). Diluted and basic weighted average shares are the same, as potentially dilutive shares are anti-dilutive.

Diluted net ~~loss~~income or (loss) per share is computed similarly to basic net ~~loss~~income or (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if such additional shares were dilutive. Options, warrants, preferred stock and shares associated with the conversion of debt to purchase approximately ~~37.2~~16.7 million and ~~36.6~~27.6 million shares of common stock were outstanding at March 31, ~~2019~~2020 and December 31, ~~2018,~~2019, respectively, but were excluded from the computation of diluted net loss per share at December 31, 2019 due to the anti-dilutive effect on net loss per share.

For the Three Months Ended March 31,
(Unaudited)

2019

2018

Net loss
$(934,532)
$(563,319)
Adjustments for convertible debt - as converted


Interest on convertible debt
  50,000
  60,000
Amortization of debt discount on convertible debt
  17,534
  8,037
Net loss attributable to common shareholders
$(866,998)
$(495,282)
Weighted average number of shares of common stock outstanding:


Basic and diluted
  124,659,307
  122,229,959
Net loss attributable to common shareholders per share:


Basic and diluted
$(0.01)
$(0.00)

	For the Three Months Ended March 31, (Unaudited)
	2020	2019

Net Income (Loss)	$2,619,261	$(934,532)
Adjustments for convertible debt - as converted
Interest on convertible debt	40,689	50,000
Amortization of debt discount on convertible debt	-	17,534
Net income (loss) attributable to common shareholders	$2,659,950	$(866,998)
Weighted average number of shares of common stock outstanding:
Basic	126,802,819	124,659,307
Diluted	144,941,677	124,659,307
Net income (loss) attributable to common shareholders per share:
Basic	$0.02	$(0.01)
Diluted	$0.02	$(0.01)

The following provides a reconciliation of the shares used in calculating the per share amounts for the periods presented:

	For the Three Months
	Ended March 31
	(Unaudited)
	2020	2019
Numerator:
Net Income (Loss)	$2,619,261	$(934,532)

Denominator:
Basic weighted-average shares	126,802,819	124,659,307
Effect of dilutive securities
Warrants	16,798,858	-
Convertible Debt	-	-
Options	830,000	-
Preferred Stock	510,000	-
Diluted Weighted Average Shares	144,941,677	124,659,307

Net Income (Loss) Per Common Share:
Basic	$0.02	$(0.01)
Diluted	$0.02	$(0.01)

Note: Warrants, options and preferred stock for the three months ended March 31, 2019 are not included in the computation of diluted weighted average shares as such inclusion would be anti-dilutive.

Income (loss) from Operations Data:

Income (Loss) from Operations	$2,659,409	$(868,030)
Basic and Diluted Weighted
Average Shares
Basic	126,802,819	124,659,307
Diluted	144,941,677	124,659,307
Basic and Diluted Income (loss) Per Common Share
Basic	$0.02	$(0.01)
Diluted	$0.02	$(0.01)

Revenue Recognition

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-09,Revenue from Contracts with Customers (Topic 606),. The Company recognizes revenue when ~~there~~we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is ~~persuasive evidence~~distinct and identify those that ~~an arrangement exists, title~~are performance obligations.

The Company must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and ~~risk~~whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of ~~loss have passed, delivery has occurred, or the services have been rendered, the sales~~transaction price ~~is fixed or determinable and collection of the related receivable is reasonably assured.~~ in step (iv) above.

Title and risk of loss generally pass to our customers upon shipment.

Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Shipping and handling costs charged to customers are included in Product Revenues. The associated expenses are treated as fulfillment costs and are included in Cost of Revenues. Revenues are reported net of sales taxes collected from Customers.

Disaggregation of Revenue

The following table presents our revenues disaggregated by revenue source.

~~Net Revenue~~

Product and Service Revenue

	For the three months ended March 31, (Unaudited)		For the three months ended March 31, (Unaudited)
	2019	2018	2020	2019
SteraMist Product	$1,029,000	$1,092,000	$6,638,000	$1,029,000
Service and Training	224,000	220,000	415,000	224,000
Total	$1,253,000	$1,312,000	$7,053,000	$1,253,000

Revenue by Geographic Region

	For the three months ended March 31, (Unaudited)		For the three months ended March 31, (Unaudited)
	2019	2018	2020	2019
United States	$1,136,000	$945,000	$3,569,000	$1,136,000
International	117,000	367,000	3,484,000	117,000
Total	$1,253,000	$1,312,000	$7,053,000	$1,253,000

Product revenue includes sales from our standard and customized equipment, solution and accessories sold with our equipment. Revenue is recognized upon transfer of control of promised products to customers in an amount that reflects the consideration we expect to receive in exchange for those ~~products or services.~~products.

Service and training revenue include sales from our high-level decontamination and service engagements, validation of our equipment and technology and customer training. Service revenue is recognized as the agreed upon services are rendered to our customers in an amount that reflects the consideration we expect to receive in exchange for those services.

Costs to Obtain a Contract with a Customer

We apply a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling expenses. ~~These costs include our internal sales force compensation program and certain partner sales incentive programs as we have determined annual compensation is commensurate with annual sales activities.~~

Contract Balances

As of March 31, ~~2019,~~2020 and December 31, ~~2018~~2019 we did not have any unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

Arrangements with Multiple Performance Obligations

Our contracts with customers may include multiple performance obligations. We enter into contracts that can include various combinations of products and services, which are primarily distinct and accounted for as separate performance obligations.

Significant Judgments

Our contracts with customers for products and services often dictate the terms and conditions of when the control of the promised products or services is transferred to the customer and the amount of consideration to be received in exchange for the products and services.

Equity Compensation Expense

We account for equity compensation expense ~~using the Black Scholes model~~ in accordance with FASB ASC 718, “Compensation—Stock Compensation.” Under the provisions of FASB ASC 718, equity compensation expense ~~cost~~ is estimated at the grant date based on the award’s fair value.

On July 7, 2017, our shareholders approved the 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan authorizes the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance units/shares. Up to 5,000,000 shares of common stock are authorized for issuance under the 2016 Plan. Shares issued under the 2016 Plan may be either authorized but unissued shares, treasury shares, or any combination thereof. Provisions in the 2016 Plan permit the reuse or reissuance by the 2016 Plan of shares of common stock for numerous reasons, including, but not limited to, shares of common stock underlying canceled, expired, or forfeited awards of stock-based compensation and stock appreciation rights paid out in the form of cash. Equity compensation expense will typically be awarded in consideration for the future performance of services to us. All recipients of awards under the 2016 Plan are required to enter into award agreements with the Company at the time of the award; awards under the 2016 Plan are expressly conditioned upon such agreements. For the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, we issued 400,000 and ~~300,000~~400,000 shares of common stock, respectively, out of the 2016 Plan.

Concentrations of Credit Risk

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and cash equivalents. We maintain cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation limit of $250,000 at times during the year.

Long-Lived Assets Including Acquired Intangible Assets

We assess long-lived assets for potential impairments at the end of each year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the asset. In evaluating long-lived assets for impairment, we measure recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows the assets are expected to generate. If our long-lived assets are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair market value. We base the calculations of the estimated fair value of our long-lived assets on the income approach. For the income approach, we use an internally developed discounted cash flow model that includes, among others, the following assumptions: projections of revenues and expenses and related cash flows based on assumed long-term growth rates and demand trends; expected future investments to grow new units; and estimated discount rates. We base these assumptions on our historical data and experience, industry projections, micro and macro general economic condition projections, and our expectations. We had no long-lived asset impairment charges for the three months ended March 31, ~~2019~~2020 and ~~2018.~~2019.

Advertising and Promotional Expenses

We expense advertising costs in the period in which they are incurred. Advertising and promotional expenses for the three months ended March 31, ~~2019~~2020 and ~~2018~~2019 were approximately $46,000 and $40,000, ~~and $54,000, respectively~~respectively.

Research and Development Expenses

We expense research and development expenses in the period in which they are incurred. For the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, research and development expenses were approximately ~~$93,000~~$59,000 and ~~$132,000, respectively.~~

~~Shipping and Handling Costs~~

We include shipping and handling costs relating to the delivery of products directly from vendors to the Company in cost of sales. Other shipping and handling costs, including third-party delivery costs relating to the delivery of products to customers, are classified as a general and administrative expense. Shipping and handling costs included in general and administrative expense were approximately $39,000 and $51,000 for the three months ended March 31, 2019 and 2018,$93,000, respectively.

Business Segments

We currently have one reportable business segment due to the fact that we derive our revenue primarily from one product. A breakdown of revenue is presented in “Revenue Recognition” in Note 2 above.

Recent Accounting Pronouncements

~~In January 2017, the FASB issued ASU No. 2017-04,~~ ~~Simplifying the Test for Goodwill Impairment~~, to simplify the test for goodwill impairment by removing Step 2. An entity will, therefore, perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, recognizing an impairment charge for the amount by which the carrying amount exceeds the fair value, not to exceed the total amount of goodwill allocated to the reporting unit. An entity still has the option to perform a qualitative assessment to determine if the quantitative impairment test is necessary. ASU No. 2017-04 is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. Adoption of ASU No. 2017-04 is prospective.None applicable.

NOTE 3. INVENTORIES

Inventories consist of the following at:

	March 31, 2019 (Unaudited)	December 31, 2018	March 31, 2020 (Unaudited)	December 31, 2019
Finished goods	$2,493,188	$2,782,014	$613,060	$2,364,786
Raw Materials			22,469	50,428
Inventory Reserve	(100,000)		-	(100,000)
	$2,393,188	$2,682,014	$635,529	$2,315,214

NOTE 4. VENDOR DEPOSITS

At March 31, 2020 and December 31, 2019, we maintained vendor deposits of $1,266,560 and $141,052, respectively, for open purchase orders for inventory.

NOTE 4.5. PROPERTY AND EQUIPMENT

Property and equipment consist of the following at:

March 31,
2019
(Unaudited)

December 31,
2018

Furniture and fixtures
$280,042
$277,976
Equipment
  1,322,910
  1,300,139
Vehicles
  60,703
  60,703
Computer and software
  153,324
  143,579
Leasehold improvements
  355,898
  355,898
Tenant Improvement Allowance
  405,000
  405,000

  2,577,877
  2,543,295
Less: Accumulated depreciation
  1,048,970
  954,704

$1,528,907
$1,588,591

	March 31, 2020 (Unaudited)	December 31, 2019
Furniture and fixtures	$357,236	$357,236
Equipment	1,292,860	1,355,014
Vehicles	60,703	60,703
Computer and software	181,182	166,598
Leasehold improvements	362,898	362,898
Tenant Improvement Allowance	405,000	405,000
	2,659,880	2,707,449
Less: Accumulated depreciation	1,402,049	1,339,585
	$1,257,831	$1,367,864

For the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, depreciation was ~~$84,468~~$78,563 and ~~$70,361,~~$84,468, respectively. For the three months ended March 31, 2020 and 2019, amortization of tenant improvement allowance ~~in the amount of~~was $9,798 and was recorded as lease expense and included within general and administrative expense on the consolidated statement of operations.

NOTE 5.6. INTANGIBLE ASSETS

Intangible assets consist of patents and trademarks related to our Binary Ionization Technology. We amortize the patents over the estimated remaining lives of the related patents. The trademarks have an indefinite life. Amortization expense was ~~$92,377~~$93,347 and $92,377 for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively.

Definite life intangible assets consist of the following:

	March 31, 2019 (Unaudited)	December 31, 2018	March 31, 2020 (Unaudited)	December 31, 2019
Intellectual Property and Patents	$2,848,300		$2,906,507
Less: Accumulated Amortization	2,201,653	2,109,276	2,573,101	2,479,754
Intangible Assets, net	$646,647	$739,024	$333,406	$426,753

Indefinite life intangible assets consist of the following:

Trademarks	$496,792		$512,257

Total Intangible Assets, net	$1,143,439	$1,235,816	$845,663	$939,010

Approximate future amortization ~~over the next five years~~ is as ~~follows:~~follows:

Year Ended:	~~Amount~~
	Amount
April 1 – December 31, ~~2019~~2020	$~~277,000~~
~~December 31, 2020~~	~~370,000~~279,000
December 31, 2021	-3,000
December 31, 2022	-3,000
December 31, 2023	-3,000
December 31, 2024	3,000
Thereafter	42,000
	$~~647,000~~333,000

NOTE 6.7. LEASES

In April 2018, we entered into a 10-year lease agreement for a new 9,000-square-foot facility that contains office, warehouse, lab and research and development space in Frederick, Maryland. The lease agreement was scheduled to commence on December 1, 2018 or when the property was ready for occupancy. The agreement provided for annual rent of $143,460, an escalation clause that increases the rent 3% year over year, a landlord tenant improvement allowance of $405,000 and additional landlord work as discussed in the lease agreement. We took occupancy of the property on December 17, 2018 and the lease was amended in March 2019 to provide for a 4-month rent holiday and a commencement date of April 1, 2019. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.

The balances for our operating lease where we are the lessee are presented as follows within our condensed consolidated balance sheet:

~~Operating leases:~~	~~March 31,~~ ~~2019~~ ~~(Unaudited)~~
~~Assets:~~
~~Operating lease right-of-use asset~~	$~~703,823~~
~~Liabilities:~~
~~Current Portion of Long-Term Operating Lease~~	$~~23,436~~
~~Long-Term Operating Lease, Net of Current Portion~~	~~1,089,316~~
	$~~1,112,752~~

Operating leases:	March 31, 2020 (Unaudited)	December 31, 2019
Assets:
Operating lease right-of-use asset	$664,198	$674,471
Liabilities:
Current Portion of Long-Term Operating Lease	$73,851	$71,510
Long-Term Operating Lease, Net of Current Portion	1,015,465	1,034,413
	$1,089,316	$1,105,923

The components of lease expense are as follows within our condensed consolidated statement of operations:

~~General and Administrative Expenses~~:	~~Three Months Ended March 31,~~ ~~2019~~ ~~(Unaudited)~~
~~Operating lease expense~~	$~~39,644~~

	Three Months Ended March 31, 2020 (Unaudited)	Three Months Ended March 31, 2019 (Unaudited)

Operating lease expense	$39,329	$39,644

Other information related to leases where we are the lessee is as follows:

		~~March 31,~~ ~~2019~~ ~~(Unaudited)~~
~~Weighted-average remaining lease term:~~
~~Operating leases~~		~~10.00 years~~

~~Discount rate:~~
~~Operating leases~~		~~7.00%~~

	March 31, 2020 (Unaudited)	December 31, 2019
Weighted-average remaining lease term:
Operating leases	9.00 years	9.25 years

Discount rate:
Operating leases	7.00%	7.00%

Supplemental cash flow information related to leases where we are the lessee is as follows:

	Three Months Ended March 31, 2020 (Unaudited)	Three Months Ended March 31, 2019 (Unaudited)
Cash paid for amounts included in the measurement of lease liabilities:	$35,865	$-

As of March 31, ~~2019,~~2020, the maturities of our operating lease liability are as follows:

Year Ended:	Operating Lease
April 1 - – December 31, ~~2019~~2020	$~~65,753~~
~~December 31, 2020~~	~~146,688~~110,823
December 31, 2021	151,088
December 31, 2022	155,621
December 31, 2023	160,290
December 31, 2024	165,098
Thereafter	~~910,280~~745,183
Total minimum lease payments	~~1,589,720~~1,488,103
Less: Interest	~~476,968~~398,787
Present value of lease obligations	~~1,112,752~~1,089,316
Less: Current portion	~~23,436~~73,851
Long-term portion of lease obligations	$~~1,089,316~~1,015,465

As previously reported in our Annual Report on Form 10-K for the year ended December 31, 2018 and under legacy lease accounting (ASC 840), future minimum lease payments under non-cancellable leases as of December 31, 2018 were as follows:

~~Year Ended:~~	~~Operating Lease~~
~~December 31, 2019~~	$~~102,000~~
~~December 31,2020~~	~~147,000~~
~~December 31,2021~~	~~151,000~~
~~December 31,2022~~	~~156,000~~
~~December 31,2023~~	~~160,000~~
~~Thereafter~~	~~923,000~~
	$~~1,639,000~~

NOTE 7.8. CAPITALIZED SOFTWARE DEVELOPMENT COSTS

In accordance with ASC 985-20 we capitalized certain software development costs associated with updating our continuing line of product offerings. AsCapitalized software development costs consist of the following at:

	March 31, 2020
	(Unaudited)	December 31, 2019
Capitalized Software Development Costs	$125,704	$125,704
Less: Accumulated Amortization	(41,901)	(31,426)
	$83,803	$94,278

Amortization expense for the three months ended March 31, 2020 and 2019 ~~a total of $125,704, of development costs are reported on our condensed consolidated balance sheet.~~was $10,475 and $0, respectively.

NOTE 8.9. CONVERTIBLE DEBT

In March and May 2017, we closed a private placement transaction in which we issued to certain accredited investors unregistered senior callable convertible promissory notes (the “Notes”) and three-year warrants to purchase an aggregate of 999,998 shares of common stock at an exercise price of $0.69 per share in exchange for aggregate gross proceeds of $6,000,000. The Notes bear interest at a rate of 4% per annum. $5,300,000 in principal was originally scheduled to mature on August 31, 2018 and $700,000 in principal was originally scheduled to mature on November 8, 2018, unless earlier redeemed, repurchased or converted. The Notes are convertible at the option of the holder into common stock at a conversion price of $0.54 per share. Subsequent to September 1, 2017, we may redeem the Notes that are scheduled to mature on August 31, 2018 at any time prior to maturity at a price equal to 100% of the outstanding principal amount of the Notes to be redeemed, plus accrued and unpaid interest as of the redemption date. Prior to November 8, 2018, we may redeem the Notes that are scheduled to mature on such date at any time prior to maturity at a price equal to 100% of the outstanding principal amount of the Notes to be redeemed, plus accrued and unpaid interest as of the redemption date. Interest on the Notes is payable semi-annually in cash on February 28 and August 31 of each year, beginning on August 31, 2017. Interest expense related to the Notes for the three months ended March 31, 2020 and 2019 was $40,689 and ~~2018 was~~ $50,000, ~~and $60,000,~~ respectively.

The warrants were valued at $62,559 using the Black-Scholes pricing model with the following assumptions: expected volatility: 104.06% –111.54%; expected dividend: $0; expected term: 3 years; and risk-free rate: 1.49%–1.59%. We recorded the warrants’ relative fair value of $61,904 as an increase to additional paid-in capital and a discount against the related Notes.

The debt discount was amortized over the life of the Notes using the effective interest method. Amortization expense for the three months ended March 31, 2020 and 2019, was $0 and ~~2018, was~~ $17,534, ~~and $8,037,~~ respectively.

In February and March 2018, we extended the maturity date of the Notes— we extended the maturity date to April 1, 2019 for $5,300,000 of principal on the Notes and to June 8, 2019 for the remaining $700,000 Note. No additional consideration was paid or accrued by us. The stated rate of the Notes was unchanged, and the estimated fair value of the new debt approximates its carrying amount (principal plus accrued interest at the date of the modification). We determined that the modification of these Notes is not a substantial modification in accordance with ASC 470-50, “Modifications and Extinguishments”.

In May 2018, we offered a noteholder the option to convert its Note at a reduced conversion price of $0.46. The noteholder accepted and converted at such price. Pursuant to the terms of the conversion offer, an aggregate of $700,000 of principal and $5,212 of accrued interest outstanding under the Note were converted into 1,877,960 shares of common stock. We recognized an induced conversion cost of $57,201 related to the conversion.

In December 2018, a noteholder redeemed a note with a principal balance of $300,000 in exchange for $150,000 in cash. We recognized a gain on redemption of convertible note income in the amount of $150,000 as a result of the transaction.

On March 30, 2019, the ~~two-remaining~~two remaining noteholders agreed to extend the maturity dates of their notes totaling $5,000,000 to April 3, 2020. As part of the extensions, we agreed that if we do not make payment on or before the new maturity dates, after five (5) days written notice, the holders will have the right, but not the obligation, to convert the notes into our common shares at a conversion price of $0.11 per share or a total of 45,454,545 shares. All other provisions of the notes remain unchanged. We determined that the modification of these Notes is not a substantial modification in accordance with ASC 470-50, “Modifications and Extinguishments”.

In March 2020, convertible notes with a principal balance of $4,500,000 were converted into 8,333,332 shares of our common stock at a conversion price of $0.54 per share and the remaining outstanding balance of $500,000 was repaid in the form of cash. With respect to the 999,998 warrants issued as part of the convertible note transaction, 799,999 warrants expired in March 2020. In March 2020, 83,333, warrants were exercised, and 116,666 warrants expired in May 2020.

Convertible notes consist of the following at:

March 31,
2019
(Unaudited)

December 31,
2018

Convertible notes
$5,000,000
$5,000,000
Initial discount
  (53,873)
  (53,873)
Accumulated amortization
  53,873
  36,339
Convertible notes, net
$5,000,000
$4,982,466

	March 31, 2020 (Unaudited)	December 31,
Convertible notes	$-	$5,000,000
Initial discount	-	(53,873)
Accumulated amortization	-	53,873
Convertible notes, net	$-	$5,000,000

NOTE 9.10. SHAREHOLDERS’ EQUITY

Our Board of Directors (the “Board”) may, without further action by our shareholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of such preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of the Company before any payment is made to the holders of our common stock. Furthermore, the Board could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of our common stock.

Convertible Series A Preferred Stock

Our authorized Convertible Series A Preferred Stock, $0.01 par value, consists of 1,000,000 shares. At March 31, ~~2019~~2020 and December 31, ~~2018,~~2019, there were 510,000 shares issued and outstanding. The Convertible Series A Preferred Stock is convertible at the rate of one share of common stock for one share of Convertible Series A Preferred Stock.

Convertible Series B Preferred Stock

Our authorized Convertible Series B Preferred Stock, $1,000 stated value, 7.5% cumulative dividend, consists of 4,000 shares. At March 31, ~~2019~~2020 and December 31, ~~2018,~~2019, there were no shares issued and outstanding, respectively. Each share of Convertible Series B Preferred Stock may be converted (at the holder’s election) into two hundred shares of our common stock.

Common Stock

During the three months ended March 31, ~~2018, we issued 300,000 shares of common stock valued at $30,000 to members of our board of directors (see Note 11).~~

~~During the three months ended March 31,~~ 2019, we issued 400,000 shares of common stock valued at $44,000 to members of our board of directors (see Note ~~11)~~12).

During the three months ended March 31, 2020, we issued 400,000 shares of common stock valued at $48,000 to members of our board of directors (see Note 12).

In March 2020, 8,333,332 shares of common stock were issued in connection with the conversion of convertible notes payable aggregating $4,500,000 (see Note 9).

In March 2020, 83,333 shares of common stock were issued in connection with the exercise of warrants for which we received proceeds of $57,500.

Stock Options

In January 2018, we issued options to purchase an aggregate of 100,000 shares of common stock to our Chief Operating Officer, valued at $11,780. The options have an exercise price of $0.12 per share and expire in January 2023. The options were valued using the Black-Scholes model using the following assumptions: volatility: 146%; dividend yield: 0%; zero coupon rate: 2.27%; and a life of 5 years.

In January 2018, we issued options to purchase an aggregate of 20,000 shares of common stock to our Scientific Advisory Board members, valued at $1,810 in total. The options have an exercise price of $0.10 per share and expire in January 2028. The options were valued using the Black-Scholes model using the following assumptions: volatility: 147%; dividend yield: 0%; zero coupon rate: 2.41%; and a life of 10 years.

In January 2019, pursuant to an employment agreement, we issued options to purchase an aggregate of 250,000 shares of common stock to our Chief Operating Officer, valued at $24,694. The options have an exercise price of $0.11 per share and expire in January 2024. The options were valued using the Black-Scholes model using the following assumptions: volatility: 144%; dividend yield: 0%; zero coupon rate: 2.47%; and a life of 5 years. The value of the options was expensed in the fourth quarter of 2018 and included in accrued expenses at December 31, 2018.

In January 2019, we issued options to purchase an aggregate of 50,000 shares of common stock to our Chief Financial Officer, valued at $4,483. The options have an exercise price of $0.10 per share and expire in January 2024. The options were valued using the Black-Scholes model using the following assumptions: volatility: 143%; dividend yield: 0%; zero coupon rate: 2.58%; and a life of 5 years.

In January 2020, we issued two options to purchase an aggregate of 250,000 shares of common stock to the COO at an exercise price of $0.10 and $0.12 per share pursuant to her employment agreement with the Company. The options were valued at a total of $23,595 and have a term of 5 years. We utilized the Black-Scholes method to fair value the options received by the COO with the following assumptions: volatility, 135%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 5 years. The grant date fair value of each share of common stock underlying the options was $0.09 and $0.10. The value of the stock option was included in accrued expenses at December 31, 2019.

The following table summarizes stock options outstanding as of March 31, ~~2019~~2020 and December 31, ~~2018:~~2019:

	March 31, 2019 (Unaudited)		December 31, 2018		March 31, 2020 (Unaudited)		December 31, 2019
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price
Outstanding, beginning of period	320,000	$0.52	200,000	$0.76	620,000	$0.32	320,000	$0.52
Granted	300,000	$0.11	120,000	$0.12	250,000	0.11	300,000	0.11
Exercised	—				-
Expired					(40,000)	2.10	—
Outstanding, end of period	620,000	$0.32	320,000	$0.52	830,000	$0.17	620,000	$0.32

Options outstanding and exercisable by price range as of March 31, ~~2019~~2020 were as follows:

Outstanding Options	Outstanding Options	Average Weighted	Exercisable Options		Outstanding Options	Average Weighted	Exercisable Options
Range	Number	Remaining Contractual Life in Years	Number	Weighted Average Exercise Price	Number	Remaining Contractual Life in Years	Number	Weighted Average Exercise Price

$0.05	20,000	1.78	20,000	$0.05	20,000	0.77	20,000	$0.05
$0.10	70,000	5.97	70,000	$0.10	220,000	4.85	220,000	$0.10
$0.11	250,000	4.76	250,000	$0.11	250,000	3.76	250,000	$0.11
$0.12	100,000	3.78	100,000	$0.12	200,000	3.77	200,000	$0.12
$0.27	40,000	5.76	40,000	$0.27	40,000	4.76	40,000	$0.27
$0.55	100,000	6.85	100,000	$0.55	100,000	5.85	100,000	$0.55
$2.10	40,000	0.76	40,000	$2.10
	620,000	4.79	620,000	$0.32
					830,000	4.28	830,000	$0.17

Stock Warrants

~~We did not issue any warrants during the three months ended March 31, 2018.~~

In January 2019 we issued a warrant to purchase 1,000,000 shares of common stock to the CEO at an exercise price of $0.10 per share pursuant to an employment agreement. The warrant was valued at $89,654 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by the CEO with the following assumptions: volatility, 143%; expected dividend yield, 0%; risk free interest rate, 2.58%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was $0.09.

In January 2019 we issued a warrant to purchase 250,000 shares of common stock to an employee at an exercise price of $0.12 per share. The warrant was valued at $21,931 and has a term of 3 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 148%; expected dividend yield, 0%; risk free interest rate, 2.55%; and a life of 3 years. The grant date fair value of each share of common stock underlying the warrant was $0.09. The value of the warrants was expensed in the fourth quarter of 2018 and included in accrued expenses at December 31, 2018.

In January 2020 we issued a warrant to purchase 1,250,000 shares of common stock to the CEO at an exercise price of $0.15 per share pursuant to an employment agreement. The warrant was valued at $164,201 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by the CEO with the following assumptions: volatility, 136%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was $0.13.

In January 2020 we issued a warrant to purchase 41,667 shares of common stock to an employee at an exercise price of $0.12 per share. The warrant was valued at $3,594 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 135%; expected dividend yield, 0%; risk free interest rate, 1.58%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was $0.09. The value of the warrants was expensed in the fourth quarter of 2019 and included in accrued expenses at December 31, 2019.

In February 2020 we issued a warrant to purchase 150,000 shares of common stock to an employee at an exercise price of $0.15 per share. The warrant was valued at $18,571 and has a term of 3 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 155%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 3 years. The grant date fair value of each share of common stock underlying the warrant was $0.12.

The following table summarizes the outstanding common stock warrants as of March 31, ~~2019~~2020 and December 31, ~~2018:~~2019:

	March 31, 2019 (Unaudited)		December 31, 2018		March 31, 2020 (Unaudited)		December 31, 2019
	Number of Warrants	Weighted Average Exercise Price	Number of Warrants	Weighted Average Exercise Price	Number of Warrants	Weighted Average Exercise Price	Number of Warrants	Weighted Average Exercise Price
Outstanding, beginning of period	26,550,611	$0.34	35,501,411	$0.33	17,240,523	$0.39	26,550,611	$0.34
Granted	1,250,000	0.10	250,000	0.08	1,441,667	0.12	1,300,000	0.11
Exercised	-				(83,333)	(0.69)	-
Expired	(1,000,000)	(0.30)	(9,200,800)	(0.30)	(1,799,999)	(0.47)	(10,610,088)	(0.23)
Outstanding, end of period	26,800,611	$0.33	26,550,611	$0.34	16,798,858	$0.36	17,240,523	$0.39

Warrants outstanding and exercisable by price range as of March 31, ~~2019~~2020 were as follows:

Outstanding Warrants	Outstanding Warrants		Exercisable Warrants		Outstanding Warrants		Exercisable Warrants
Exercise Price	Number	Average Weighted Remaining Contractual Life in Years	Number	Weighted Average Exercise Price	Number	Average Weighted Remaining Contractual Life in Years	Number	Weighted Average Exercise Price
$0.08	250,000	4.65	250,000	$0.08	250,000	3.65	250,000	$0.08
$0.10	1,265,000	4.51	1,265,000	$0.10	1,265,000	3.51	1,265,000	$0.10
$0.12	3,750,000	3.67	3,750,000	$0.12	3,791,667	2.69	3,791,667	$0.12
$0.12	4,000,000	0.54	4,000,000	$0.12
$0.14					50,000	4.05	50,000	$0.14
$0.15					1,400,000	4.63	1,400,000	$0.15
$0.17	10,000	3.57	10,000	$0.17	10,000	2.57	10,000	$0.17
$0.27	250,000	2.75	250,000	$0.27	250,000	1.75	250,000	$0.27
$0.29	10,125,613	1.55	10,125,613	$0.29	4,615,525	1.91	4,615,525	$0.29
$0.30	2,300,000	1.39	2,300,000	$0.30	1,200,000	0.89	1,200,000	$0.30
$0.32	250,000	2.50	250,000	$0.32	250,000	1.50	250,000	$0.32
$0.42	250,000	2.25	250,000	$0.42	250,000	1.25	250,000	$0.42
$0.50	250,000	2.00	250,000	$0.50	250,000	1.00	250,000	$0.50
$0.55	100,000	1.83	100,000	$0.55	100,000	0.83	100,000	$0.55
$0.69	999,998	0.97	999,998	$0.69	116,666	0.10	116,666	$0.69
$1.00	3,000,000	1.09	3,000,000	$1.00	3,000,000	0.09	3,000,000	$1.00
	26,800,611	1.81	26,800,611	$0.33	16,798,858	2.01	16,798,858	$0.36

There were no unvested warrants outstanding as of March 31, ~~2019.~~2020.

NOTE ~~10.~~11. COMMITMENTS AND CONTINGENCIES

Legal Contingencies

We may become a party to litigation in the normal course of business. In the opinion of management, there are no legal matters involving us that would have a material adverse effect upon our financial condition, results of operations or cash flows. In addition, from time to time, we may have to file claims against parties that infringe on our intellectual property.

Product Liability

As of March 31, ~~2019,~~2020, and December 31, ~~2018,~~2019, there were no claims against us for product liability.

SARS CoV-2 coronavirus

On March 11, 2020 the World Health Organization declared the SARS CoV-2 coronavirus a global pandemic and recommended containment and mitigation measures worldwide. We are monitoring this closely. We have been identified as an essential disinfectant and decontamination vendor by various agencies and countries. Our operations being essential have been materially affected by the coronavirus outbreak to date, as demand for our product and services is increasing. The uncertain nature of its spread globally may or may not impact our business operations resulting from quarantines of employees, customers and suppliers as well as potential travel restrictions in areas affected or may be affected in the future.

NOTE ~~11.~~12. CONTRACTS AND AGREEMENTS

Agreements with Directors

In December 2017, we increased the annual board fee to directors to $40,000, to be paid in cash on a quarterly basis, with the exception of the audit committee chairperson, whose annual fee we increased to $45,000, also to be paid in cash on a quarterly basis. Director compensation also includes the annual issuance of our common stock.

For the three months ended March 31, ~~2018,~~2019, we issued an aggregate of ~~300,000~~400,000 shares of common stock that were valued at ~~$30,000~~$44,000 to members of our board of directors.

For the three months ended March 31, ~~2019,~~2020, we issued an aggregate of 400,000 shares of common stock that were valued at ~~$44,000~~$48,000 to members of our board of directors.

Other Agreements

In June 2015, we launched the TOMI Service Network (“TSN”). The TSN is a national service network composed of existing full-service restoration industry specialists that have entered into licensing agreements with us to become Primary Service Providers (“PSPs”). The licensing agreements grant protected territories to PSPs to perform services using our SteraMist™® platform of products and also provide for potential job referrals to PSPs whereby we are entitled to referral fees. Additionally, the agreement provides for commissions due to PSPs for equipment and solution sales they facilitate to other service providers in their respective territories. As part of these agreements, we are obligated to provide to the PSPs various training, ongoing support and facilitate a referral network call center. As of March 31, ~~2019,~~2020, we had entered into 89140 licensing agreements in connection with the launch of the TSN. The licensing agreements contain fixed price minimum equipment and solution orders based on the population of the territories granted pursuant to the licensing agreements. The nature and terms of our TSN agreements may represent multiple deliverable arrangements. Each of the deliverables in these arrangements typically represent a separate unit of accounting. As of January 1, 2020, we have removed the exclusivity portion of our service partner company agreements

NOTE ~~12.~~13. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following at:


	March 31, 2019 (Unaudited)	December 31, 2018	March 31, 2020 (Unaudited)	December 31, 2019
Commissions	$271,750	$136,631	$237,466	$112,102
Payroll and related costs	142,497	144,359	224,752	167,689
Director fees	41,250		41,250
Sales Tax Payable	30,973	11,296	27,810	21,814
Accrued warranty (Note 13)	30,000
Accrued warranty (Note 14)			60,000	30,000
Other accrued expenses	63,956	51,663	64,458	77,257
Total	$580,426	$415,199	$655,736	$450,112

NOTE ~~13.~~14. ACCRUED WARRANTY

Our manufacturer assumes warranty against product defects for one year from the sale to customers, which we extend to our customers upon sale of the product. We assume responsibility for product reliability and results. The warranty is generally limited to a refund of the original purchase price of the product or a replacement part. We estimate warranty costs based on historical warranty claim experience.

The following table presents warranty reserve activities at:

	March 31, 2019 (Unaudited)	December 31, 2018	March 31, 2020 (Unaudited)	December 31, 2019
Beginning accrued warranty costs	$30,000	$5,000	$30,000
Provision for warranty expense	1,324	47,454	31,864	2,609
Settlement of warranty claims	(1,324)	(22,454)	(1,864)	(2,609)
Ending accrued warranty costs	$30,000		$60,000	$30,000

NOTE 15. CUSTOMER DEPOSITS

At March 31, 2020 and December 31, 2019, there were customer deposits of $1,017,533 and $0, respectively on future equipment orders. In the first quarter of 2020, we began requiring a 50% customer deposit on placing most orders and payment in full prior to delivery on most orders to mitigate credit risk and to improve liquidity.

NOTE 16. INCOME TAXES

For the three months ended March 31, 2020 and 2019, our provision for income tax was $0. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits, which are, on a more likely than not basis, not expected to be realized in accordance with ASC guidance for income taxes. As of March 31, 2020 and December 31, 2019, we recorded a valuation allowance of $4,743,000 and $5,580,000, respectively for the portion of the deferred tax assets that we do not expect to be realized. The valuation allowance on our net deferred taxes decreased by $837,000 during the three months ended March 31, 2020, primarily due to U.S. deferred tax assets incurred in the current period that could be realized. Management believes that based on the available information, it is more likely than not that the remaining U.S. deferred tax assets will not be realized, such that a valuation allowance is required against U.S. deferred tax assets. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

NOTE ~~14.~~17. CUSTOMER CONCENTRATION

The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s accounts receivable.

As of March 31, ~~2019 and~~2020, one customer accounted for 12% of our accounts receivable. As of December 31, ~~2018, two~~2019, three customers accounted for ~~41% and~~ 37% of accounts receivable ~~respectively.~~.

~~Two customers~~For the three months ended March 31, 2020, sales made to one international customer / distributor accounted for ~~45%~~31% of net ~~revenue for~~revenue. For the three months ended March 31, 2019, ~~and three~~two customers accounted for ~~33%~~45% of net ~~revenue for the three months ended March 31, 2018.~~revenue.

NOTE ~~15.~~18. SUBSEQUENT EVENTS

On April 21, 2020, TOMI Environmental Solutions, Inc. (the "Company") received $410,700 in loan funding from the Paycheck Protection Program (the "PPP") established pursuant to the recently enacted Coronavirus Aid, Relief, and Economic Security Act of 2020 (the "CARES Act") and administered by the U.S. Small Business Administration ("SBA"). The unsecured loan (the "PPP Loan") is evidenced by a promissory note of the Company, ~~has evaluated subsequent events through~~dated April 21, 2020 (the "Note") in the principal amount of $410,700 with City National Bank (the "Bank"), the lender.

Under the terms of the Note and the PPP Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. The term of the Note is two years, though it may be payable sooner in connection with an event of default under the Note. To the extent the loan amount is not forgiven under the PPP, the Company will be obligated to make equal monthly payments of principal and interest beginning on the date that is seven months from the ~~financial statements were issued and up to the time of filing~~date of the ~~financial statements with~~Note, until the ~~SEC.~~maturity date.

In April ~~2019, TOMI entered into a distribution agreement with an Israeli~~2020 the company ~~Cleancor Technologies Ltd., an advanced solution company for the industrial cleaning~~issued 100,000 warrants to its Chief Executive Officer, 50,000 warrants to its Chief Operating Officer and ~~repair of water and fire damages.~~

~~In April 2019, we secured product registration for our SteraMist~~®~~BIT~~™~~Solution in Israel.~~50,000 warrants to its Chief Financial Officer, all exercisable at $0.50 per share.

In May ~~2019, we recorded a sale~~2020, 3,116,666 warrants expired reducing the number of ~~over $400,000 for the Kansas Department of Health in the United States.~~outstanding warrants to 13,912,192

~~Item~~Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the related notes included elsewhere in this Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, as filed with the SEC. In addition to our historical condensed consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Form 10-Q, particularly in Part II, Item 1A, “Risk Factors.”

Overview

TOMI Environmental Solutions, Inc. (“TOMI”, “we” and “our”) is a global provider of disinfection and decontamination essentials through our premier Binary Ionization Technology® (BIT™) platform, under which we manufacture, license, service and sell our SteraMist® brand of products, including SteraMist® BIT™, a hydrogen peroxide-based ~~mist/fog.~~fog or mist.

TOMI’s ~~cold plasma~~SteraMist is a patented technology that produces ionized Hydrogen Peroxide (iHP™,) using plasma science created under a ~~mist/fog consisting of Reactive Oxygen Species, mainly hydroxyl radicals (“~~.~~OH”). This technology converts TOMI’s BIT~~™grant by ~~solution, which contains only one active ingredient, a low-percentage hydrogen peroxide solution to~~.~~OH by passing it through an atmospheric cold plasma arc.~~

~~In response to the 2001 Anthrax spore attacks,~~ the United States Defense Advanced Research Projects Agency ~~(“DARPA”) and a leading defense company, Titan Corporation, developed~~(DARPA). TOMI’s EPA registered BIT™ Solution is composed of a low concentration of hydrogen peroxide converted to ~~defend against chemical and biological agents under a DARPA grant. In June 2005, L-3~~iHP™ ~~Communications, Inc. (“L-3 Communications”)~~after passing the trade secret blended solution including its sole active ingredient of 7.8% hydrogen peroxide through an atmospheric cold plasma arc. The newly formed iHP™fog and mist consists of submicron’s to 3-micron radical particles that are carried throughout the treatment area in a ~~leading defense company, acquired~~fog or mist moving with the ~~technology~~same velocity and characteristics of a gas. This allows the ionized hydrogen peroxide fog or mist to affect all surfaces and space throughout the targeted treatment area, over, above and beyond the ability of a manual cleaning processes. iHP™damages pathogenic organisms through the ~~acquisition~~oxidation of ~~Titan Corporation.~~proteins, carbohydrates, and lipids. SteraMist® ~~In 2011, TOMI recognized~~no-touch disinfection and or decontamination treat areas mechanically, causing cellular disruptions and/or dysfunctions resulting in a 6-log (99.9999%) and greater kill or inactivation of all pathogens in the ~~importance of this disruptive and innovative technology and,~~treatment area.

~~after two years of negotiations, won the right to purchase the technology from L-3 Communications. Subsequently, we began the~~ ~~process~~ ~~of registering~~ ~~BIT~~™~~with the Environmental Protection Agency (“EPA”), using good laboratory practice testing.TOMI introduced~~ SteraMist® Binary Ionization Technology® allows a facility to ~~the commercial market~~have a hospital-healthCare EPA registered tool and solution to replace manual cleaning technology, upgrade existing protocols, and limit liability in ~~June 2013, using our inherited and pre-existing EPA mold label. In June 2015, we successfully registered~~a facility when it comes to resistant infectious pathogens. SteraMist® BIT™ ~~as a hospital-healthcare disinfectant and broad-spectrum general use disinfectant for use as a misting/fogging agent, at which time our technology became~~is the first ~~EPA-registered hospital-healthcare disinfectant~~EPA registered solution and ~~equipment~~system combination on the market. BIT™is also listed on EPA’s List G, H, K, L, M and N for Norovirus, MRSA, C.diff, Ebola, Avian flu or Influenza and SARS-CoV-2 respectively.TOMI ~~proudly~~ maintains this registration in 50 states, Canada, and ~~we continuously update our label with additional pathogens.~~approximately 22 other countries.

Markets

TOMI’s SteraMist® products are designed to address a ~~panoply~~wide spectrum of industries using ~~iHP~~ionized Hydrogen Peroxide (iHP™). Our operations are organized into four main divisions based on our current target industries: Hospital-Healthcare, Life Sciences, TOMI Service Network (TSN) and Food Safety. In addition, TOMI is able to bring SteraMist® efficacy to each division through scheduled iHP® Service in both routine and emergency capacities. SteraMist® technology and iHP® Service are available both domestically and internationally.

Products

We continue to offer our customers a wide range of innovative products designed to be easily incorporated into their existing disinfection and decontamination ~~procedures. In addition,~~procedures and protocols. Additionally, we offer integrated facility equipment installations known as Custom Engineered Systems, routine & emergency iHP™ Service, validations and qualifications, and onsite performance maintenance ~~needs all~~requests – Each of ~~which~~these are structured to address ~~iHP~~® ~~service~~the unique disinfection and decontamination needs ~~globally.~~of our customers worldwide.

Divisions

Hospital-Healthcare

~~TOMI currently counts 42~~TOMI’s hospital-healthcare ~~facilities as customers,~~customer list continues to grow with ~~an expanding number each year. In 2018, TOMI launched~~ the ~~E-Z~~closing of every quarter. TOMI’s SteraMist® Hospital Disinfection Cart, an all-in-one cart that houses our handheld point-and-spray SteraMist® Surface Unit ~~as well as~~and accompanying ~~supplies. This product is designed~~supplies, continues to ~~make the terminal cleaning process of patient rooms more efficient than traditional manual cleaning methods. We believe that our E-Z~~assist medical staff with emergency response and turnaround for new and established protocols. The SteraMist® ~~Disinfection Cart will allow our~~Hospital disinfection cart allows customers within the ~~Hospital-Healthcare~~hospital-healthcare industry to address concerns of the ~~growing concern regarding the increasing high level~~cross-contamination of ~~transference of~~dangerous bacteria and viral pathogens ~~including~~in which some can lead to HAIs stemming from existing and emerging pathogens, as well as multiple drug resistant organisms (MDRO’s) ~~leading~~. SteraMist® Technology allows a manual cleaning protocol lasting 90 minutes to ~~HAI’s from hospital and healthcare related environmental surfaces and equipment~~be reduced to ~~patients and healthcare workers.~~55 minutes, including the changing of bed linens, as confirmed by the Shield Study at UCLA. This mobile consolidation solution has resulted in remarkable results for facilities utilizing our technology. Previously published results of N95 mask disinfection efficacy were shortly followed by the official listing of SteraMist as a List N disinfectant against the SARS-CoV-2 Coronavirus.

Life Sciences

TOMI’s SteraMist®. Environment System, ~~iHP Decontamination Complete Room,~~Custom Engineered Solutions, the SteraMist® Select Surface Unit, custom iHP™ implementation to decontamination chambers and cage washers, and our iHP®™ Service Division, are designed to be tailored to provide a complete room solution to address the regulatory inspections of disinfecting/decontaminating and Installation Qualification (IQ)-Operational Qualification (OQ)–Performance Qualification (PQ) validation processes within the life sciences industry. In addition, TOMI has worked alongside many research universities and government agencies in the effort to test SteraMist efficacy on the disinfection and re-use of N95 masks and other equivalent PPE, with results that indicate that the use of SteraMist iHP™ will not reduce mask efficacy, including on those containing 10% or less of cellulose. SteraMist has also been included in studies observing the effects of iHP disinfection on the reduction of Syphacia obvelata pinworm ova presence in rodent cages, which indicated positive results.

TOMI Service Network

The TOMI Service Network, or TSN, is ~~our~~an expansive network ~~comprised~~consisting of ~~outside~~third-party professionals specializing in a wide array of disciplines who are exclusively licensed and trained to use the SteraMist® products. ~~TSN~~TOMI sells, trains, and services a wide array of professional remediation companies in the use of SteraMist®~~. These~~ through the TSN division. This allows for increased accessibility of Binary Ionization Technology to facilities in need of local routine and emergency disinfection and decontamination.

Many of these companies specialize in mold ~~abatement, water damage~~remediation, treatment of water-damaged areas (including damage from CAT ~~1 though 3~~1-3 water loss) ~~and~~, fire damage, as well as professional specialists that are certified and practice in the area of forensic restoration. Currently, the TSN ~~is comprised~~features a number of ~~companies~~professionals throughout both the United States and ~~Canada. TSN members use~~Canada, with some utilizing SteraMist® as a standalone service ~~as well as~~and others incorporating ~~our products~~SteraMist into their existing business ~~models. TOMI derives a continuous revenue stream from our TSN customers through recurring purchases of our BIT~~™ ~~solution.~~models and methods.

~~Our~~Sales of BIT™ Solution make up a large amount of our consistent revenue stream, and members of the TOMI Service Network are a large portion of those recurring sales. As of January 1, 2020, we have removed the exclusivity portion of our service partner company agreements, allowing us to expand our network and further penetrate existing markets. The TSN network ~~continues~~has grown significantly to ~~grow and currently~~date in 2020, with the total number of ~~TSN provider contracts fully executed to date is eighty-nine (89)~~service providers currently at one hundred and sixty (160), ~~expanding~~which has expanded our network membership across ~~thirty-five (35)~~forty-four (44) U.S. States and two (2) Canadian provinces. ~~Our service providers have over one hundred and fifty (150 )~~Currently, there are approximately 295 SteraMist® ~~with BIT technology~~ units in the field ~~allowing for rapid deployment for use in the control~~across all members of ~~a biological outbreak and border security nationally and internationally.~~TSN™.

Food Safety

~~Food Safety~~ ~~is becoming~~As one of our ~~largest~~newest targeted markets, Food Safety presents significant potential as ~~we believe it presents a clear potential~~an opportunity for substantial ~~growth. This is~~growth with continued product research and compliance testing. With the food safety industry in ~~light of~~North America coming under closer scrutiny with the implementation and enforcement of new and existing rules in the United States under the FDA Food Safety Modernization Act and in Canada under the Safe Food for Canadians Act and the Safe Food for Canadians Regulations, the latter two of which became effective in January 2019. This is in part due to this increased focus on concerns within the food safety industry in North America and abroad. Weestablished guidelines, our consultants have ~~consultants submitting to the EPA and FDA~~submitted a request to expand our current labels ~~from~~to include a 1% acceptable concentration of hydrogen peroxide. This concentration has previously been approved by the ~~treatment of~~USDA and FDA for direct food and crop application, and will allow SteraMist to expand use sites beyond food processing machinery, restaurants, and food contact areas to ~~include direct food and crop applications. This market is rapidly developing for TOMI~~assist in compliance with the ~~assistance of our co-marketing partner Arkema, a division of Total S.A., a French multinational integrated oil~~newly-established Food Safety Modernization Act guidelines set in place by the FDA, as well as the Safe Food for Canadians Act and ~~gas company.~~Safe Food for Canadians Regulations in Canada.

~~We intend to target the following segments, with an initial emphasis on the profitable organic market:~~

●

~~Growing crops~~

●

~~Seeds~~

●

~~Packaging facilities~~

●

~~Food storage (produce, meats, fish)~~

●

~~Food transportation vehicle’s~~

●

~~Food processing~~

●

~~Cannabis~~

~~In each area, our main~~Our primary objective is to prevent and/or minimize food decay without ~~utilizing~~the use of harsh chemicals that leave toxic ~~residues. This~~residues, which could create ana lucrative opportunity to supplement or replace current pesticides and fungicides currently being used by ~~these~~ industry leaders.

Business Highlights and Recent Events

~~Research Studies & Product Development~~SARS CoV-2 coronavirus.

On March 11, 2020 the World Health Organization declared the SARS CoV-2 coronavirus a global pandemic and recommended containment and mitigation measures worldwide. We have been identified as a disinfectant and decontamination vendor by various agencies and countries. We have been working relentlessly with organizations to address the concerns and provide solutions for disinfecting and decontamination of the SARS CoV-2 coronavirus. The outbreak has increased the demand for TOMI products and services. We anticipate that the outbreak will change requirements and processes for decontamination and disinfecting worldwide, of which SteraMist will be a solution. We are working with our existing and new customers to develop and/or upgrade their existing processes and requirements for decontamination and disinfecting.

We have been addressing the increased demand for our products as follows: (i) cooperation of our supply chain to expedite product, (ii) increase our staff to be able to receive and ship orders to meet customer timelines (iii) increase our customer service support to answer questions and solve issues and (iv) working with our Tomi service network to ensure that resources are deployed in a timely manner. In addition, we increased our production capacity and will be entering into an agreement with a second vendor to build our SteraMist products.

Customers:

In response to the increased demand due to the global pandemic outbreak, our customer list grew substantially on the first quarter. Globally, we added eighty-one (81) new customers across all our divisions for the three months ended March 31, 2020. This represents a six hundred and eight-six (686%) percent increase over the first quarter of 2019. We anticipate that the new customers will continue to order products beyond the outbreak.

Our TSN division added thirty-six (36) new service providers for the three months ended March 31, 2020, an increase of 1700% compared to the first quarter of 2019. TSN was the key division to address the demand for decontamination and disinfecting services during the outbreak. We anticipate that TSN will continue to service the new customers as a result of the outbreak, as customers update their requirements and processes with these services.

Our Hospital-Healthcare division added eighteen (18) new facilities for the three months ended March 31, 2020 which represents 800% increase compared to the prior year period.

Our Life Sciences customer base showed continued growth with the addition of eighteen (18) new customers for the three months ended March 31, 2020. This represents a 533% increase compared to the same prior year period.

Revenues:

Total revenue for the three months ended March 31, 2020 and 2019, was approximately $7,053,000 and $1,253,000, respectively, representing an increase of $5,800,000, or 463% compared to the same prior year period. The increase in revenue was attributable to increased global demand for disinfection and infectious disease control products in response to the SARS CoV-2 coronavirus global pandemic. In the first quarter we saw significant demand for our product with our Hospital-Healthcare and TSN sales as a result of the SARS CoV-2 coronavirus global pandemic. We expect the revenue to continue to grow as our customers update their requirements, processes and procedures to include decontamination and disinfecting services into their regular routines.

SteraMist product-based revenues for the three months ended March 31, 2020 and 2019, were approximately $6,638,000 and $1,029,000, representing an increase of $5,609,000 or 545% when compared to the same prior year period. The growth is attributable to increased mobile equipment orders and solution orders from our existing customer base as well as our new customers. We expect solution orders to continue to grow as the new and existing customers adopt new processes and requirements for decontamination and disinfecting services. We cannot determine the frequency or quantities at this time, as the industry is rapidly evolving.

Our service-based revenue for the three months ended March 31, 2020 and 2019, was approximately $415,000 and $224,000, respectively, representing a year over year increase of 85%. The increase in our service-based revenue was attributable to higher training sales recorded in the first quarter to onboard new customers.

Our domestic revenue for the three months ended March 31, 2020 and 2019 was $3,569,000 and $1,136,000, respectively, an increase of $2,433,000, or 214% when compared to the same prior year period. The increase was primarily due to the growth in our TSN network and in our Hospital-Healthcare customers.

Internationally, our revenue for the three months ended March 31, 2020 and 2019, was approximately $3,484,000 and $117,000, respectively, representing an increase of $3,367,000 or 2,878% when compared to the first quarter of 2019. The increase in our international revenue was attributable to the increased use and expansion of our SteraMist® line of products in Canada, Europe, Asia and the Middle East. We expect our international revenue to continue to grow as more countries adopt our products and services as well as change their decontamination and disinfecting requirements.

Our Hospital-Healthcare revenues grew by approximately 6,000% in the first quarter of 2020 when compared to the same prior year period. The growth was primarily attributable to the significant demand for our product as a result of the SARS CoV-2 coronavirus global pandemic. We anticipate continued growth in this sector as hospital-healthcare facilities review and adopt new processes and technologies to address current and future outbreaks. We cannot predict the frequency or volume of orders as the world’s response to decontamination and disinfecting is evolving. However, we anticipate continued growth moving into 2020.

We expanded TSN membership and grew TSN revenue in the first quarter of 2020 by 727% when compared to the same prior year period. The growth in revenue was largely due to the increased demand for decontamination technologies in response to the SARS CoV-2 coronavirus a global pandemic.

Events:

Following are the significant events during the first quarter 2020:

●

January 29, 2020 – TOMI SteraMist® prepared to deploy to fight SARS CoV-2 coronavirus.

●

February 4, 2020 - TOMI Receives China CDC Registration Making SteraMist® the Disinfection Industry Standard in China

●

February 27, 2020 - SteraMist® Takes the Fight to the SARS CoV-2 coronavirus. Worldwide - China, Hong Kong, Thailand, Singapore, Israel and the United Kingdom

●

March 2, 2020 - SteraMist® Declared Official Decontamination Technology of Seoul City Metropolitan Transit Systems

●

March 10, 2020 - SteraMist® is Mobilized to Aid in the Control SARS-CoV-2 coronavirus in Daegu-Kyungbuk Province, South Korea

●

March 11, 2020 - SteraMist® is Prepared to Fight SARS-CoV-2 coronavirus in Thailand

●

March 11, 2020 – The World Health Organization declared the SARS CoV-2 coronavirus a global pandemic and recommended containment and mitigation measures worldwide. We have been identified as a disinfectant and decontamination vendor by various agencies and countries, ensuring TOMI’s continued operation through established federal and state quarantine measures while simultaneously increasing the demand for TOMI products and services. We have been working relentlessly with organizations to address the concerns and provide disinfection and decontamination solutions for the SARS CoV-2 coronavirus.

●

March 16, 2020 - SteraMist® Deployed to Fight SARS-CoV-2 coronavirus in United States

●

March 16, 2020 – SteraMist® qualified to meet the EPA Emerging Viral Pathogen Guidance for Antimicrobial Pesticides with the SteraMist®Environment System for room fogging/misting against SARS-CoV-2 coronavirus, the novel coronavirus that causes COVID-19 and was added to the EPA N List against SARS-CoV-2.

●

March 25, 2020 - SteraMist® utilized in Singapore to help reopen mosques

●

During the first quarter of 2020, we experienced the following:

●

Sold substantially all of our equipment inventory, with a backlog and demand for 91 additional units,

●

Most New equipment orders require a 50% deposit, with balance due on most orders prior to final shipment of products.

●

Increased demand on solution re-orders as disinfecting and decontamination procedures have increased exponentially across the world,

●

Service revenue grew exponentially as the outbreak spread and demand for disinfecting and decontamination services increased,

●

Exclusivity in TSN was revoked as demand surged and new providers requested equipment, solution and training to provide disinfecting and decontamination services,

●

New channels were opened as decontamination and disinfecting processes are updated and implemented, including but not limited to, fire departments, morgues, FAA, police departments, county and state health departments, cruise ships, infectious disease research facilities, military and ambulances,

●

Convertible notes with a principal balance of $4,500,000 were converted into 8,333,332 shares of our common stock at a conversion price of $0.54 per share, and the remaining outstanding balance of $500,000 was repaid.

●

Staffing – increased demand has led to the hiring and onboarding of additional employees to assist in a wide variety of company operations, from accounting, procurement, customer satisfaction to quality control.

Subsequent Events:

Following are the significant events during the second quarter 2020:

●

April 23, 2020 – Study results showcasing SteraMist® efficacy on the disinfection and reuse of N95 masks published.

●

April 27, 2020 – SteraMist® Deployed to Meet Urgent Need for Decontamination and Reuse of N95 Masks for Healthcare Workforce

●

April 28, 2020 – SteraMist® Disinfection Used to Combat Coronavirus Throughout the United States with Expansion of its Service Network

●

April 29, 2020 – SteraMist® Demand for SteraMist BIT Solution Surges

●

TOMI continues to see increased domestic and international demand for its products over the foreseeable future. TOMI has expanded its markets into the private aviation sector in Germany, multiple market segments in Indonesia and hospital-healthcare, military and homeland security in Singapore.

Research Studies

We continue to participate in a large multi-year federal funded study, aknown as the “SHIELD study”, that compares hospital manual cleans to a SteraMist® mechanical clean. ~~This~~Preliminary results collected by the current hospitals in the study is ~~being conducted at Los Angeles Public Health Hospitals; UCLA Olive View Medical Center, Harbor-UCLA Medical Center. Preliminary results have shown that there has been~~showing a ~~significant~~ decrease in the transference of pathogens resulting in HAIs and C. difficile infections in the rooms that used SteraMist® for their terminal clean, as compared to the rooms that have been manually cleaned. ~~Future results will be released as obtained from~~The University of Michigan, a recognized teaching university hospital, joined the ~~study’s lead investigators, which we believe will expand our presence~~California hospitals in this Shield Study in the ~~hospital healthcare market.~~second quarter 2020, allowing for additional collection of data to validate the value of SteraMist® technology in hospitals.

InProduct Development

We have added four new products to our growing line of products:

●

The SteraMist Surface Unit has been upgraded to a new model, the ~~first~~HHA-103. This model keeps the same functionality of the previous model with the featured addition of a new Harting™ Camlock port to the unit. This upgraded port allows for a more secure connection between the applicator and the Surface Unit, effectively latching the connection in place and eliminating the presence of any possible pulling or tilting that could compromise the connection integrity over time. Additionally, the unit features additional room within the unit for applicator and accessory storage.

●

A single applicator build-in unit for decontamination chambers and cage washers, which was recently successfully validated at the University of Houston.

●

A decontamination cart for a Pfizer facility. We will be designing and engineering a second SteraMist® mobile decontamination cart for this same facility by the second quarter of ~~2019,~~2020.

●

A stainless-steel mobile 90-degree applicator and the answer to the mobile treatment and decontamination of BSC cabinets and isolators. The 90-degree applicator product has led to a partnership with a large design and manufacturing company of washing and contamination control systems, and we ~~also focused~~plan on installing an all-in-one disinfection solution to Gnotobiotic Housings with our partner.

During 2020, we will continue our focus on improving our SteraMist® Environment System and the development of ~~our own~~a proprietary software that will be integrated into the next generation of ~~the Environment System.~~SteraMist® equipment, both mobile and permanent. The new software will improve communication between our equipment and the end user’s system, provide improved reporting results and simplify the overall usage of the system itself. ~~During~~We are in the ~~first quarter~~final testing and validation phase of ~~2019, we reached feasibility with~~ the ~~software being developed.~~new Environment System prototype, expecting to begin commercialization in 2020.

We ~~continue to focus~~are in the design phase with our partner Arkema and their client (a global food storage and safety company) on ~~providing resources towards additional efficacy studies, iHP™ applications, and expansion into new use sites and smaller enclosures. In March of 2019, we delivered~~ an ~~iHP Mobile Decontamination Chamber~~engineered concept for the ~~Pfizer facility~~decontamination of large industrial food warehouse facilities. The concept is a six (6) applicator fully automated fogging system permanently mounted on a hydraulic lift that is capable of coverage in Sanford, North Carolina. This first model was custom designed to the facility’s specifications and requirements to decontaminate tools and calibration equipment. With the design of this custom unit, TOMI is excited to expand on this design by manufacturing a new product line not only for its Life Sciences, but its Hospital-HealthCare and Food Safety divisions.

high-volume spaces. We ~~continue to evaluate product validation across verticals which include but~~ are ~~not limited to: Life Science -studies on monkeypox and pinworms. Healthcare - studies on resistant TB and C.~~ ~~auris~~ ~~a deadly Japanese fungus plaguing our healthcare system worldwide. We currently are registered by the EPA for treatment of rooms infected with C.~~ ~~auris~~ ~~because of our EPA status on list K and C.~~ ~~diff~~ ~~claim but many international countries want a specific claim for C.~~ ~~auris.~~ TSN - mycotoxins the potential allergen left after treating residential and commercial building for mold. Food safety - approval for direct food use, we are registering a lower percentage hydrogen peroxide product for direct food spray use and continuing our testing in ~~the cannabis industry to control many~~early phases of the ~~pathogens affecting their industry which is quickly becoming a global industry with plaguing mold issues.~~project and don’t have an expected commercialization date.

Registrations & Intellectual Property (IP):

~~In January 2019, TOMI received a no objection letter from Canada, amending its BIT~~™~~Solution registration to include Salmonella and Norovirus. Our Canadian label now holds similar efficacy claims with our U.S. EPA label.~~

In February ~~2019, we added our Canadian label to the Organic Materials Review Institute (“OMRI”) certifying that our product meets the Canadian organic standards.~~

~~In March 2019, TOMI~~2020, SteraMist equipment and ~~its new customer in Brisbane, Australia who services critical environments with iHP~~®BIT solution was registered with the ~~Australian Therapeutic Goods Association~~Chinese Center for Disease Control and Prevention (China CDC). After a three (3) year-long submission process, we recently received ~~a client identification number.~~

~~TOMI has been actively pursuing~~confirmation that two (2) separate registrations - SteraMist equipment registration ~~in mainland China for 24 months. We~~and BIT solution registration - have now ~~successfully passed~~been officially approved and registered with the ~~Chinese CDC requirements~~China CDC. SteraMist is now the industry standard for disinfection throughout all of China. This registration allows China to take advantage of SteraMist disinfection and ~~have hired~~decontamination in a ~~CDC consultant to pass~~variety of verticals such as healthcare, pharmaceutical, commercial and residential, schools, and throughout the ~~flame off to and carry the registration flame forward.~~Also, we have been shoring up our trademarks for SteraMist China and registering all our new patents. We have identified a Chinese customer that we expect will generate revenue upon receipt of the Chinese CDC registration in 2019.

TOMI’s technology and its solution through its Israeli partner is registered by the State of Israel, Minister of Health’s Medical Technology, Information and Research Division under the Medical Device Department.community.

~~Operations:~~

In January 2019, TOMI and Arkema Inc. a global leader in the hydrogen peroxide industry entered into an exclusive global co-marketing and supply agreement. The agreement provides that the parties will develop the market for TOMI’s technology using our SteraMist brand of products for food safety applications, improving the speed and effectiveness of disinfection solutions to the industry.

~~In February 2019, TOMI entered into a distribution agreement with Ster-Pharma Cleaning BV, a specialized company in Disinfecting & Sterilizing Cleanrooms and Operating Rooms in the Netherlands.~~

In March ~~2019,~~2020, our Binary Ionization Technology® (BIT™) Solution qualified to meet the EPA Emerging Viral Pathogen Guidance for Antimicrobial Pesticides with the SteraMist Environment System for room fogging/misting against SARS-CoV-2, the novel coronavirus that causes COVID-19. The EPA Emerging Viral Pathogen Guidance for Antimicrobial Pesticides is important because the occurrence of emerging viral pathogens is less common and predictable than established pathogens and there are currently no other EPA-registered disinfectant product labels with claims against COVID-19. The SARS-CoV-2, the novel coronavirus that causes COVID-19 qualifies as an emerging viral pathogen. Our Binary Ionization Technology (BIT) Solution, used exclusively in tandem with SteraMist equipment including the Surface Unit and Environment System, is currently listed on List G for Norovirus, List H for MRSA, List K for Clostridium difficile spores, List L for Ebola, List M for H1N1, and now List N: Disinfectants for Use Against SARS-CoV-2. With labeled efficacy for large and small enveloped viruses in addition to other pathogens, we ~~were audited by Pfizer Global Supply Manufacturing and Supplier Quality Assessments and were reported~~have confidence this EPA addition will support client efforts to ~~be “Acceptable”, allowing us to continue expanding SteraMist~~®~~implementation into Pfizer facilities. In 2019, management further focused and allocated resources towards expanding quality control procedures and protocols based on recommendations received during~~reduce the ~~audit.~~ongoing spread of the COVID-19.

Financial Operations Overview

Our financial position as of March 31, ~~2019~~2020 and December 31, ~~2018~~2019 was as follows:

	March 31, 2019 (Unaudited)	December 31, 2018	March 31, 2020 (Unaudited)	December 31, 2019
Total shareholders’ equity	$2,245,000	$2,995,000	$8,324,000	$890,000
Cash and cash equivalents	$1,196,000	$2,005,000	$3,756,000	$897,000
Accounts receivable, net	$2,028,000	$2,146,000	$3,146,000	$1,495,000
Inventories, net	$2,393,000	$2,682,000	$636,000	$2,315,000
Prepaid expenses	$259,000	$302,000	$171,000	$188,000
Deposits	$189,000	$109,000
Current liabilities	$1,308,000	$1,700,000
Vendor Deposits			$1,267,000	$141,000
Current liabilities (excluding convertible notes)			$2,610,000	$1,302,000
Convertible notes payable, net	$5,000,000	$4,982,000	$-	$5,000,000
Long-term liabilities (excluding long-term convertible notes)	$1,089,000	$402,000
Working capital	$4,757,000	$5,544,000
Long-term liabilities			$1,015,000	$1,034,000
Working Capital (excluding convertible notes)			$6,365,000	$3,734,000
Working Capital (including convertible notes)			$6,365,000	$(1,266,000)

During the three months ended March 31, ~~2019,~~2020, our liquidity positions were affected by the following:

●

Net cash ~~used in~~provided from operations of approximately ~~$649,000.~~$3,316,000

●

~~Costs incurred to develop software~~Vendor deposits of approximately ~~$126,000.~~$1,267,000

●

~~Purchase of property and equipment~~Customer deposits of approximately ~~$35,000.~~$1,018,000

●

Conversion of convertible notes payable with a principal balance of $4,500,000 into shares of common stock

●

Repayment of convertible note payable with a principal balance of $500,000

Results of Operations for the Three Months Ended March 31, ~~2019~~2020 Compared to the Three Months Ended March 31, ~~2018~~2019

Three Months Ended March 31,

(Unaudited)

2019

2018

Revenues, Net
$1,253,000
$1,312,000
Gross Profit
$759,000
$821,000
Total Operating Expenses (1)
$1,627,000
$1,317,000
Loss from Operations
$(868,000)
$(496,000)
Total Other Income (Expense)
$(67,000)
$(67,000)
Net Loss
$(935,000)
$(563,000)
Basic Net Loss per Share
$(0.01)
$(0.00)
Diluted Net Loss per Share
$(0.01)
$(0.00)

	Three Months Ended	Three Months Ended
	March 31, 2020 (Unaudited)	March 31, 2019 (Unaudited)

Revenue, Net	$7,053,000	$1,253,000
Gross Profit	$4,488,000	$759,000
Total Operating Expenses (1)	$1,829,000	$1,627,000
Income (Loss) from Operations	$2,659,000	$(868,000)
Total Other Income (Expense)	$(40,000)	$(67,000)
Net Income (Loss)	$2,619,000	$(935,000)
Basic Net Income (Loss) per share	$0.02	$(0.01)
Diluted Net Income (Loss) per share	$0.02	$(0.01)

(1)

Includes approximately ~~$81,000~~$183,000 and ~~$13,000~~$81,000 in non-cash equity compensation expense for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively.

Net Revenue

Sales

~~Our~~Total revenue for the three months ended March 31, ~~2019~~2020 and ~~2018~~2019, was approximately $7,053,000 and $1,253,000, ~~and $1,312,000, respectively.~~respectively, representing an increase of $5,800,000, or 463% compared to the same prior year period. The ~~quarter over quarter decline~~increase in revenue iswas attributable to increased global demand for disinfection and infectious disease control products in response to the SARS CoV-2 coronavirus global pandemic. In the first quarter we saw significant demand for our product with our Hospital-Healthcare and TSN sales as a result of ~~fluctuations in~~the SARS CoV-2 coronavirus global pandemic. We expect the revenue to continue to grow as our ~~sales cycle based on~~customers update their requirements, processes and procedures to include decontamination and disinfecting services into their regular routines.

In the first quarter, we saw a rapid expansion of our customer ~~mix~~list and ~~attributable~~continued to ~~the timing of~~see strong reorders for solution from our ~~higher priced equipment orders that result in a high dollar volume of sales.~~existing customers. Our new customer ~~mix ranges between commercial businesses, local, state and federal governmental agencies which result in a longer sales cycle.~~

The first quarter of 2019 flat revenue was primarily due to where we are in the customer cycle. TOMI products are early in the product and customer adoption cycle. Due to the early adoption, we continue to generate business from new customers, however, the existing customer re-order of additional equipment are at a slower pace due to the assessment and integration of our technology into the on-going customer operations.pipeline remains strong. As customers mature through the product and adoption cycle and our sales pipeline converts to revenue, we expect to have more predictable sales quarter over quarter.

~~During the first quarter 2019, we continued to increase our customer base and saw positive trends in our repeat orders for solution and consumables by our growing customer base.~~

In January 2019, we were engaged by LYNX Product Group, a manufacturer that designs, builds, and has a reputation of premium brand washing equipment for a national renounced well-known military medical center based in the DC metro area to implement a SteraMist Environment System with special programing features to work as the decontamination solution for a cage washer that will be moved into the facility shortly.

In February 2019, Paragon BioServices, an industry-leading development and manufacturing organization focusing on biopharmaceuticals, reached out to TOMI with the need for disinfecting/decontaminating their facility with SteraMist.

We continue to build our sales force and added a new domestic Life Sciences Manufacturing Representative team with a focus on lyophilizers (freeze dryers) that can be made in cleanroom configurations running iHP™~~in the Biosafety Cabinet (BSC) and lyophilizer for many of their current clients.~~

Product and Service Revenue

	For the three months ended March 31, (Unaudited)		For the three months ended March 31, (Unaudited)
	2019	2018	2020	2019
SteraMist Product	$1,029,000	$1,092,000	$6,638,000	$1,029,000
Service and Training	224,000	220,000	415,000	224,000
Total	$1,253,000	$1,312,000	$7,053,000	$1,253,000

Revenue by Geographic Region

For the three months ended March 31,
(Unaudited)

2019

2018

United States
$1,136,000
$945,000
International
117,000
367,000
Total
$1,253,000
$1,312,000

	For the three months ended March 31, (Unaudited)
	2020	2019
United States	$3,569,000	$1,136,000
International	3,484,000	117,000
Total	$7,053,000	$1,253,000

Cost of Sales

Cost of sales was approximately ~~$493,000~~$2,565,000 and ~~$492,000~~$493,000 for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively, an increase of ~~$1,000,~~$2,072,000, in the current year period. ~~Cost~~The primary reason for the increase in cost of sales ~~can fluctuate based on~~is attributable to the increase in revenue in the current year. Our gross profit as a percentage of sales for the three months ended March 31, 2020 was 63.6% compared to 60.6% in the same prior period. The higher gross profit is attributable to the product ~~mix.~~mix in sales. As revenues continue to grow and we are able to negotiate more favorable pricing from our vendors, we anticipate that our cost per unit could decrease.

Professional Fees

Professional fees were approximately ~~$105,000~~$136,000 and ~~$106,000~~$105,000 for the three months ended March 31, 2020 and 2019, ~~and 2018,~~ respectively, ~~a decrease~~an increase of approximately ~~$1,000,~~$31,000, or 1%29%, in the current year period. Professional fees are comprised mainly of legal, accounting and financial consulting fees.

Depreciation and Amortization

Depreciation and amortization were approximately ~~$177,000~~$172,000 and ~~$163,000~~$177,000 for the three months ended March 31, 2020 and 2019, ~~and 2018,~~ respectively, ~~an increase~~a decrease of ~~$14,000,~~$5,000, or 9%3%, in the current year period. ~~The increase in depreciation expense is attributable to additional property and equipment acquired in 2018.~~

Selling Expenses

Selling expenses were approximately ~~$442,000~~$379,000 and ~~$204,000~~$442,000 for the three months ended March 31, 2020 and 2019, ~~and 2018,~~ respectively, ~~an increase~~a decrease of ~~$238,000,~~$63,000, or ~~117%~~14%, in the current year period. We continue to invest and allocate resources into our sales, marketing and advertising initiatives and have increased efforts in the current year in order to further develop our brand recognition and grow our base of customers. ~~We are hoping to see positive results~~The decline in ~~our revenue in the second half of the year directly related to the onboarding of different national sales groups during the first half of 2019. Our~~ selling expenses ~~increased in the current period as a result of the following:~~

–

~~Higher salaries~~is primarily due to ~~increases in~~a lower employee headcount in our sales ~~department.~~

–

~~Customer mix~~department as well as lower tradeshow costs in the current year period. We expect tradeshow expenses to continue to decline this year in the post CoV-2 world, as physical distancing continues to remain in effect. We expect to increase our sales team during 2020 to address the increase in the demand for our products and ~~the related commissions impact.~~

–

~~Increased tradeshow presence.~~

–

~~Continual efforts in advertising within targeted publications, Google search engine optimized campaigns, and organic brand awareness.~~

–

~~Continued investment in our Social Media presence across all platforms which has shown growth in followers, impressions, and engagements.~~

~~Selling expenses represent selling salaries and wages, trade show fees, commissions, advertising and marketing expenses.~~services.

Research and Development

Research and development expenses were approximately ~~$93,000~~$59,000 and ~~$132,000~~$93,000 for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively, a decrease of ~~$39,000,~~$34,000, or ~~30%~~36%, in the current year period. The primary reason for the decrease is attributable to the timing of costs ~~we incurred~~related to testing and studies that occurred in the current period that were capitalized as software development. Research and development expenses mainly include costs incurred in generating and supporting research on improving, extending and applying our patents in the field of mechanical cleaning and decontamination.

As we continue to introduce and maintain a new disinfection and decontamination standard in all our divisions, we will need to conduct studies, peer review and published papers. This requires effort of many of our full time employees.

~~Some of the milestones in research and development are:~~

Just recently CETA, the Controlled Environment Testing Association published a performance review on “Validating A Decontamination Protocol Utiling/ionized Hydrogen Peroxide (iHP)”. The paper validates that TOMI’s produced ionized hydrogen peroxide was effective for complete kill in the pharmacy trailer system, after achieving greater than 6-log kill in its three validation cycles. With TOMI’s solution being lower than 8% hydrogen another benefit is that it can be safely transported in the trailers to multiple locations without any restrictions. iHP will be the preferred method of sterilization for Germfree bioGoTM X Mobile Compounding Pharmacies due to its efficacy, portability and other benefits. This method should be considered in other types of facilities including mobile, modular and fixed laboratories and cleanrooms.

Developments in the shield study are very encouraging to date. One way of creating a standard in a specific industry group in hospitals is to publish peer review study and results comparing manual cleaning to our rapid SteraMist terminal clean in hospitals, the SHIELD study is just that vehicle. With that study completing its first year recently with great results TOMI feels that its track record will continue. Also, the study may expand to a very large and recognized Midwest teaching university this summer to give the study even more data as it concludes its second year.

Our division verticals are asking for more validation in areas of interest for example the life sciences division wants to see studies on monkeypox and pinworms. Healthcare wants specific studies on resistant TB and C. ~~auris~~ ~~a deadly Japanese fungus plaguing our healthcare system worldwide. We currently are registered by the EPA for treatment of rooms infected with C.~~ ~~auris~~ ~~because of our EPA status on list K and C.~~ ~~diff~~ ~~claim but many international countries want a specific claim for C.~~ ~~auris.~~ Our TSN divisions would like specific test on mycotoxins the allergen left after treating residential and commercial building for mold. Our food safety divisions wants approval for direct food use, as a result we are processing and registering a lower percentage hydrogen peroxide product for direct food spray and continuing our testing in the cannabis industry to control many of the pathogens affecting their industry which is quickly becoming a global industry with plaguing mold issues.

TOMI has been active in the first quarter filling specific requests from global pharmaceutical companies for variations of our SteraMist products to meet their individual needs. This has resulted in the addition of three new products to our growing line of products. One such product is a single pod build-in unit for the University of Houston; a second new product is a decontamination cart for a Pfizer facility that may put this new decontamination cart product into their production process worldwide; and the third is the answer to the mobile treatment and decontamination of BSC cabinets and isolators with our stainless steel mobile 900 ~~degree applicator.~~

The United States Department of Agriculture (USDA) is in its final edits of another published paper titled “Cold Plasma Enhances the Efficacy of ionized Hydrogen Peroxide in Reducing Populations of Salmonella Typhimurium and Listeria innocua on Grape tomatoes, Apples, Cantaloupe and Romaine Lettuce”, TOMI is looking forward to presentation of this paper at an upcoming national meeting and then the publication of this paper this year in a recognized international food safety journal.

TOMI has been included in the recently published Global Disinfectants Market-Trends, Insights & Forcasts by Melvin Bright. The April 2019 289 page report is on “Potential Risks from Epidemic, Drug Resistant Viruses and the Resulting Focus on Safety, Health, and Sanitation Drives Demand for Disinfectants.” The report shows that the disinfection market was a $4.48 billion market in 2018 and expects to grow and reach a $8.40 billion dollar market by 2025.same prior period.

Equity Compensation Expense

Equity compensation expense was approximately $183,000and $81,000 ~~and $13,000~~ for the three months ended March 31, 2020 and 2019, ~~and 2018, respectively.~~respectively, representing an increase of $102,000 or 136%.

Consulting Fees

Consulting fees were approximately ~~$35,000~~$82,000 and $35,000 for the three months ended March 31, 2020 and 2019, ~~and 2018.~~respectively, representing an increase of $47,000, or 133%, in the current year period. The increase is due to the timing of certain projects that occurred in the first quarter of 2020 that did not occur in the same prior year period.

General and Administrative Expense

General and administrative expense was approximately ~~$695,000~~$818,000 and ~~$664,000~~$695,000 for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively, an increase of ~~$31,000,~~$123,000, or 5%18%, in the current year period. The increase in General and administrative expense is attributable to a higher employee headcount and higher wages as well as an increase in international product registration. General and administrative expense includes salaries and payroll taxes, rent, insurance expense, utilities, office expense and product registration costs.

Other Income and Expense

Amortization of debt discount was approximately ~~$18,000~~$0 and ~~$8,000~~$17,534 for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively. Amortization of debt discount for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, consists of the amortization of debt discount on the $6,000,000 principal amount of Notes issued in March and May 2017. The debt discount was amortized over the life of the Notes utilizing the effective interest method.

Interest income was approximately ~~$1,000~~$500 and ~~$1,200~~$1,000 for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively.

Interest expense was approximately ~~$50,000~~$41,000 and ~~$60,000~~$50,000 for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively. Interest expense for the three months ended March 31, ~~2019~~2020 and ~~2018~~2019 consisted of the interest incurred on the $6,000,000 principal amount of Notes issued in March and May ~~2017.~~2017 of which $4,500,000 was converted to common stock in March, 2020 and the remaining $500,000 was paid in cash in March 2020.

Net ~~Loss~~Income (Loss)

Net ~~loss~~income was approximately ~~$935,000 and $563,000~~$2,619,000 compared to a net loss of approximately ($935,000) for the three months ended March 31, ~~2019~~2020 and ~~2018,~~2019, respectively, an increase in net income of ~~$372,000,~~$3,554,000, or ~~66%~~380%, in the current year period. The primary reasons for the ~~increased~~higher net ~~loss are~~income is attributable to:

●

~~Lower revenue~~Higher sales and gross profit of approximately ~~$59,000~~$5,800,000 and ~~$62,000, respectively~~$3,729,000, respectively;

●

Lower other expenses of approximately $27,000, offset by

●

Higher operating expenses of approximately ~~$310,000.~~$202,000;

Liquidity and Capital Resources

As of March 31, ~~2019,~~2020, we had cash and cash equivalents of approximately ~~$1,196,000~~$3,756,000 and working capital of ~~$4,757,000.~~ $6,365,000.Our principal capital requirements are to fund operations, invest in research and development and capital equipment, and the continued costs of public company filing requirements. We have historically funded our operations through debt and equity financings.

In March ~~and May 2017, we raised gross proceeds~~2020, convertible notes with a principal balance of ~~$6,000,000 through a private placement of the Notes. We issued the Notes in two tranches of $5,300,000 and $700,000, respectively, which originally~~$4,500,000 were ~~scheduled to mature on August 31, 2018 and November 8, 2018, respectively, unless earlier redeemed, repurchased or converted.~~

~~In 2018 a portion~~converted into 8,333,332 shares of our ~~convertible notes aggregating $1,000,000 principal were either converted to equity or paid.~~

~~On March 30, 2019,~~common stock at a conversion price of $0.54 per share and the remaining ~~note holders agreed to extend~~outstanding balance of $500,000 was repaid in the ~~maturity dates~~form of ~~their aggregate of $5,000,000 in notes to April 3, 2020.~~cash.

For the three months ended March 31, ~~2019 and 2018,~~2020 we ~~incurred losses~~generated income from operations of approximately ~~$868,000~~$2,659,000 and ~~$496,000, respectively. The cash used in operations was approximately $649,000 and $683,000~~ for the three months ended March 31, 2019 we incurred losses from operations of approximately ($868,000). The cash provided from operations for the three months ended March 31, 2020, was approximately $3,316,000. The cash used in operations was approximately ($649,000) for the three months ended March 31, 2019.

During the first quarter of 2020, due to the SARS CoV-2 uncertainty and ~~2018,~~to mitigate our credit risk, we modified our customer payment terms requiring a 50%-100% deposit on most equipment orders which improved our cash flows and liquidity. We had customer deposits of approximately $1,017,000 as of March 31, 2020.

As of March 31, 2020, in response to our inventory order quantities and request for expediting our products, our vendors required us to place deposits of approximately $1,267,000 on future inventory orders.

A breakdown of our statement of cash flows for the three months ended March 31, 2020 and 2019 is provided below:

Operating Activities

Cash provided by operating activities for the three months ended March 31, 2020 was approximately $3,316,000, compared to cash used in operations for the three months ended March 31, 2019 of approximately ($649,000). Our cash provided by operations improved in the current year period as a result of increased revenue, net income and customer deposits placed on future orders offset by increased accounts receivable and vendors deposits.

Investing Activities

Cash used in investing activities for the three months ended March 31, 2020 and 2019 was approximately $15,000 and $160,000, respectively. Cash used in investing activities decreased approximately $145,000 primarily due to software development costs and the acquisition of fixed assets in the prior year period.

Financing Activities

Cash used in financing activities for the three months ended March 31, 2020 and 2019 were approximately $443,000 and $0, respectively. The cash used in financing activities increased in the current period due to the repayment of the principal balance of the convertible note of $500,000 offset by proceeds from the exercise of warrants in the amount of $57,500.

Our revenues can fluctuate due to the following factors, among others:

●

Ramp up and expansion of our internal sales force and manufacturers’ representatives;

●

Length of our sales cycle;

●

Global response to the outbreak of SARS CoV-2;

●

Expansion into new territories and markets; and

●

Timing of orders from distributors.

We could incur ~~additional~~ operating losses and an increase of costs related to the continuation of product and technology development, and sales expense as we continue to grow our sales teams and geographic presence, tooling capital expenditures as we ramp up and streamline our production and administrative ~~activities.~~activities including compliance with Sox 404.

Management has taken and will endeavor to continue to take a number of actions in order to improve our results of operations and the related cash flows generated from operations in order to strengthen our financial position, including the following items:

●

Expanding our label with the EPA to further our product registration internationally;

●

Continued expansion of our internal sales force and manufacturer representatives in an effort to drive ~~domestic~~global revenue in all ~~hospital-healthcare~~ verticals;

●

~~Continued expansion of our internal sales force and manufacturer representatives in an effort to drive global revenue in the life science verticals;~~Source alternative lower-cost suppliers;

●

Expansion of international distributors; and

●

Continued growth in all of ~~TSN,~~ our new Forensic Restoration FRST sub-division and new growth in the food safety market which includes using SteraMist for increasing the storage time of pre- and post-harvest produce. Increasing transportation shelf life by installing SteraMist in semitrucks and ships that are transporting food.verticals.

We expect that the cash we generate from our core operations will generally be sufficient to cover our future capital expenditures and to pay down our near-term debt obligations, although we may choose to seek alternative financing sources.

We believe that our existing balance of cash and cash equivalents and amounts expected to be provided by operations will provide us with sufficient financial resources to meet our cash requirements for operations, working capital and capital expenditures over the next twelve months.We cannot make any assurances that management’s strategies will be effective or that any additional financing will be completed on a timely basis, on acceptable terms or at all. Our inability to successfully implement our strategies or to complete any other financing may mean that we would have to significantly reduce costs and/or delay projects, which would adversely affect our business, customers and program development, and would adversely impact us.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings. Sufficient funds may not be available to us at all or on attractive terms when needed from these sources. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. We may require additional capital beyond our currently anticipated amounts.

~~Operating Activities~~

~~Cash used in operating activities~~ for the three months ended March 31, 2019 and 2018 was approximately $649,000 and $683,000, respectively. Cash used in operating activities decreased approximately $34,000 compared to the prior year period.

~~Investing Activities~~

~~Cash used in investing activities~~ for the three months ended March 31, 2019 and 2018 was approximately $160,000 and $0, respectively. Cash used in investing activities increased $160,000 compared to the prior year period primarily due to software development costs.

~~Financing Activities~~

~~Cash used in financing activities~~ ~~for the three months ended March 31, 2019 and 2018 were $0.~~

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimation process requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. Actual results could differ materially from our estimates.

The SEC defines critical accounting policies as those that are, in management’s view, most important to the portrayal of our financial condition and results of operations and most demanding of our judgment. We consider the following policies to be critical to an understanding of our condensed consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact our results of operations, financial position and cash flows.

Revenue Recognition

Title and risk of loss generally pass to our customers upon shipment. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Shipping and handling costs charged to customers are included in Product Revenues. The associated expenses are treated as fulfillment costs and are included in Cost of Revenues. Revenues are reported net of sales taxes collected from Customers.

Disaggregation of Revenue

The following table presents our revenues disaggregated by revenue source.

Product and Service Revenue

	For the three months ended March 31, (Unaudited)
	2020	2019
SteraMist Product	$6,638,000	$1,029,000
Service and Training	415,000	224,000
Total	$7,053,000	$1,253,000

Revenue by Geographic Region

	For the three months ended March 31, (Unaudited)
	2020	2019
United States	$3,569,000	$1,136,000
International	3,484,000	117,000
Total	$7,053,000	$1,253,000

Costs to Obtain a Contract with a Customer

Contract Balances

As of March 31, ~~2019,~~2020, and December 31, ~~2018~~2019 we did not have any unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

Arrangements with Multiple Performance Obligations

Significant Judgments

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the accompanying condensed consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, inventory, fair values of financial instruments, intangible assets, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes, and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of our assets and liabilities.

Fair Value ~~Measurement~~Measurements

Level 1:

Quoted prices in active markets for identical assets or liabilities.

Level 2:

Level 3:

Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

Cash and Cash Equivalents

Accounts Receivable

Inventories

Inventories are valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventories consist primarily of finished goods.

We expense costs to maintain certification to cost of goods sold as incurred.

Property and Equipment

Leases

Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease liabilities are recorded as current portion of long-term operating lease, and within ~~other~~ long-term liabilities as long-term operating lease, net of current portion on our condensed consolidated balance sheet as of March 31, 2020 and December 31, 2019.

Capitalized Software Development Costs

Accrued Warranties

Income Taxes

~~Loss~~Net Income (Loss) Per Share

Equity Compensation Expense

Concentrations of Credit Risk

Long-Lived Assets Including Acquired Intangible Assets

We had no long-lived asset impairment charges for the three months ended March 31, 2020 and 2019.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements

See Note 2 to the Condensed Consolidated Financial Statements contained in Item 1 above.

Off-Balance Sheet Arrangements

We do not have any transactions, agreements or other contractual arrangements that constitute off-balance sheet arrangements.

~~Item~~Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 405 under the Securities Act of 1933, as amended, and Rule 12b-2 under the ~~Securities~~ Exchange Act ~~of 1934, as amended (the “Exchange Act”),~~ and are not required to disclose the information required by this Item 3 pursuant to Item 305(e) of Regulation S-K.

~~Item~~Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report on Form 10-Q. ~~Our disclosure controls and procedures are intended to ensure~~Based on that the information we are required to disclose in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated toevaluation, our ~~management, including the~~ Principal Executive Officer and Principal Financial Officer ~~to allow timely decisions regarding required disclosures.~~concluded that our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) under the Exchange Act during the period covered by this Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

~~PART~~PART II: OTHER INFORMATION

~~Item~~Item 1. Legal Proceedings.

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our results of operations, financial position or cash flows. Regardless of the outcome, any litigation could have an adverse impact on us due to defense and settlement costs, diversion of management resources and other factors.

~~Item~~Item 1A. Risk Factors.

While, as a smaller reporting company, we are not required to provide the information required by this Item 1A, you should carefully review and consider the risk factors contained in our other reports and periodic filings with the SEC, including without limitation the risk factors contained under the caption “Item 1A—Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019. The risk factors discussed in that Form 10-K do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations.

~~Item~~Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

~~Item~~Item 3. Defaults Upon Senior Securities.

None.

~~Item~~Item 4. Mine Safety Disclosures.

Not ~~applicable~~applicable.

~~Item~~Item 5. Other Information.

None.

~~Item~~Item 6. Exhibits.

The documents listed in the Exhibit Index of this Form 10-Q are incorporated herein by reference.

~~SIGNATURES~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TOMI ENVIRONMENTAL SOLUTIONS, INC.

Date: May 14, ~~2019~~2020	By:	/s/ Halden S. Shane
		Halden S. Shane
		Chief Executive Officer (Principal Executive Officer)



~~Date: May 14, 2019~~	~~By:~~	~~/s/~~ ~~Nick Jennings~~

Date: May 14, 2020	By:	/s/ Nick Jennings
		Nick Jennings
		Chief Financial Officer ~~(Principal~~ (Principal Financial Officer and Principal Accounting Officer)

~~EXHIBIT~~EXHIBIT INDEX

Incorporated by Reference

Filed

Herewith

Exhibit Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

10.1

PPP Note

31.1

Certification of Halden S. Shane, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Nick Jennings, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

~~32.1#~~32.1#

Certification of Halden S. Shane, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~32.2#~~32.2#

Certification of Nick Jennings, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

+ Indicates a management contract or compensatory plan.

# This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (Securities Act), or the Exchange AcAct.

4140

	For the Three Months Ended March 31,
	2019	2018
Cash Flow From Financing Activities:	-	-
(Decrease) In Cash and Cash Equivalents	(809,000)	(682,583)
Cash and Cash Equivalents - Beginning	2,004,938	4,550,003
Cash and Cash Equivalents – Ending	$1,195,938	$3,867,420

Supplemental Cash Flow Information:
Cash Paid For Interest	$100,000	$124,000
Cash Paid for Income Taxes	$800	$800
Non-Cash Investing and Financing Activities:
Right of Use Asset Arising from Adoption of ASC 842	$714,421	$-
Warrants and Options as Consideration for Accrued Expenses	$59,845	$-

	Balances at December 31, 2018	Effect of Adoption of New Lease Standard	Balances at January 1, 2019
Assets
Prepaid Expenses	$301,797	$(35,865)	$265,932
Operating Lease Right of Use Asset	$-	$714,421	$714,421
Liabilities
Deferred Rent	$13,215	$(13,215)	$-
Current Portion of Long-Term Operating Lease	-	-	-
Deferred Rent and Tenant Improvement Allowances	$401,734	$(401,734)	$-
Long-Term Operating Lease, Net of Current Portion	-	$1,093,505	$1,093,505
Shareholders' Equity
Accumulated Deficit	$(41,201,511)	$-	$(41,201,511)

	Three Months Ended March 31,
	(Unaudited)
	2019	2018
Revenues, Net	$1,253,000	$1,312,000
Gross Profit	$759,000	$821,000
Total Operating Expenses (1)	$1,627,000	$1,317,000
Loss from Operations	$(868,000)	$(496,000)
Total Other Income (Expense)	$(67,000)	$(67,000)
Net Loss	$(935,000)	$(563,000)
Basic Net Loss per Share	$(0.01)	$(0.00)
Diluted Net Loss per Share	$(0.01)	$(0.00)